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Abbreviations 
2D 2-dimensional  
3D  3-dimensional  
A area 
A  additive genetic effects 
AHA American Heart Association  
AIC Akaike Information Criterion  
ALARA As Low As Reasonably Achievable 
AM1 acute marginal branch 
Ao ascending aorta 
BIC Bayesian Information Criterion 
BMI body mass index 
bpm beat per minute 
C circumference 
C  common environmental effects 
CAD coronary artery disease 
CAVI  transcatheter caval valve implantation  
CI confidence interval  
cMPR curved multiplanar reformation  
CTA computed tomography angiography 
D mean diameter 
D  dominant genetic effects 
D1 diagonal 1 branch  
D2 diagonal 2 branch  
DL long diameter 
DS short diameter 
DZ dizygotic twins 
E unique environmental effects 
ECG electrocardiography 
GWAS  genome-wide association studies  
HR heart rate 
ICC intraclass correlation coefficient  
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ICT isovolumic contraction time  
IRB institutional review board  
IV intravenous 
kV kilovolt 
LA  left atrium 
LAD left anterior descending artery 
LCX circumflex artery 
LM left main coronary artery 
LV left ventricle 
LVET left ventricular ejection time  
LVOT  left ventricular outflow tract  
mAs milliampere-second 
mg milligram  
MIP maximum intensity projections  
mL/s milliliter/second 
mm Hg millimeter of mercury 
mm/s millimeter second 
MPR multiplanar reformation   
ms millisecond  
MZ monozygotic twins 
OM1 obtuse marginal 1 
P phenotype 
PDA posterior descending artery 
PEP pre-ejection period   
RA-IVC right-atrium inferior vena cava 
RCA right coronary artery 
RFCA radiofrequency catheter-ablation 
SCCT Society of Cardiovascular Computed Tomography 
TAVI  transcatheter aortic valve implantation 
TGFBR transforming growth factor-beta receptor 
TTE transthoracic echocardiography 
VRT volume rendering technique reconstructions  
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1. INTRODUCTION 
In the past years computed tomography angiography (CTA) has become a widely 
adopted non-invasive imaging technique for the direct visualization of coronary artery 
disease (CAD). High spatial resolution of current CT scanners allows for detailed 
anatomical and morphological evaluation of atherosclerotic plaques, while high 
temporal resolution enables to acquire the fast-moving coronary arteries. In addition the 
3-dimensional (3D) nature of CTA provides precise visualization of complex cardiac 
structures thus aiding in the planning of structural heart interventions such as 
transcatheter aortic valve implantation (TAVI) as one of the most successful examples.  
Cardiac CTA however is a technically demanding procedure and motion artifacts 
caused by the constant movement of the heart present the chief challenge. Therefore 
optimized timing of the acquisition window with the least motion is utmost importance 
to achieve diagnostic image quality.  
One option to assess motion-free images is the synchronization of the acquisition 
window to the phase of the cardiac cycle with minimal coronary arterial motion. 
Current guidelines report the use of prospectively ECG-triggered image acquisition [1] 
preferably in the most tranquil period of the cardiac cycle, which at low and stable heart 
rates (HR) is during mid-diastole (during diastasis) [2, 3] and in patients with high HR 
is during end-systole [4, 5].  
Another method to achieve favorable image quality is the reduction of HR. In patients 
undergoing coronary CTA HR should be <65 beats per minute (bpm) and optimally <60 
bpm to achieve excellent image quality and low effective radiation dose [6]. Metoprolol 
is the first-line β-blocker for HR lowering [7-9]. However, potential contraindications 
and side-effects (e.g. reactive airway disease, bradycardia, hypotension) might hamper 
its use in a subset of patients. During coronary CTA, short and effective HR control is 
desirable; short-lasting intravenous (IV) esmolol therefore might be a good alternative 
for metoprolol. Currently, esmolol is routinely administered in the intensive care unit 
for the treatment of acute supraventricular arrhythmias; however, administration before 
coronary CTA for HR reduction is an “off-label” indication.  
Motion-free images are the pre-requisite to assess accurate and reproducible 
measurements of anatomically complex structures. Manual adjustments might be time-
consuming, with the potential for increased intra-reader and inter-reader variability. 
DOI:10.14753/SE.2017.2024
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Commercially available semi- and fully automated software algorithms aim to 
standardize image analysis thus providing reliable measurements, which are critical for 
clinical and research applications. Computer aided analysis might provide more 
reproducible measurements, thus reduce the frequency of reader disagreements. 
Furthermore, automatic post-processing of image data, will likely increase efficacy in 
clinical practice.  
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1.1 CTA for the assessment of the coronary arteries  
The excellent image quality provided by high-resolution CT scanners enables direct and 
reliable evaluation of the coronary arteries. Prior to CTA a preliminary interpretation of 
prospectively ECG-triggered calcium score scan is performed. This allows for the 
detection of calcified lesions across the coronary arteries. Based on the area-density of 
the lesions the software generates the Agatston-score, which is calculated by 
multiplying the lesion area (mm2) by a density factor (between 1 and 4 based on the 
voxel with the highest density) [10]. 
The non-contrast examination is followed by IV administration of iodinated contrast 
agent, which enables to reach uniform enhancement among coronary arteries and 
permits direct visualization of the coronary lumen and atherosclerotic plaques. Based on 
the presence and quantity of calcified plaque components atherosclerotic lesions are 
classified into three categories: calcified, partially calcified and non-calcified plaques 
[11]. The Society of Cardiovascular Computed Tomography (SCCT) released a 
standardized diagram that is recommended for the reporting of coronary artery lesions. 
The diagram is based on the American Heart Association (AHA) coronary 
segmentation, with an addition of the ramus intermedius (segment 17) and left 
posterolateral branch (segment 18) (Figure 1) [12].  
The anatomical complexity of the coronary arteries requires cardiac specific platforms, 
which are capable to display the 3D dataset in all conventional reconstruction formats. 
These include transaxial 2-dimensional (2D) image stacks, multiplanar reformations 
(MPR), maximum intensity projections (MIP), curved multiplanar reformations 
(cMPR), and volume rendering technique (VRT) reconstructions (Figure 2).   
Artifact-free images are the most important prerequisite for the diagnostic evaluation of 
the coronary arteries. Continuous motion of the heart, calcifications, image noise and 
poor contrast enhancement might substantially degrade the quality of the exam. The 
desired temporal resolution for complete motion-free image is 19 millisecond (ms) [13]. 
Since the temporal resolution of modern CT scanners is 75-175 ms [14] motion artifacts 
are often present, especially in the midsegment of the RCA [15]. “Stairstep artifacts” or 
according to a newer terminology “misalignment artifacts” [11] occur between 
reconstruction of sequential heartbeats, mainly in patients with higher or irregular HR or 
the presence of ectopic heartbeats (Figure 2). 
DOI:10.14753/SE.2017.2024
 9 
 
Figure 1. Coronary artery segmentation diagram by the Society of Cardiovascular 
Computed Tomography (SCCT) [12] 
LM: left main; LAD: left anterior descending artery; D1: diagonal 1; D2: diagonal 2; 
LCX: circumflex artery; OM1: obtuse marginal 1; OM2: obtuse marginal 2; RCA: right 
coronary artery; PDA: posterior descending artery; R-PDA: PDA from RCA; L-PDA: 
PDA from LCX; PLB: posterolateral branch; R-PLB: PLB from RCA; L-PLB: PLB 
from LCX. Dashed lines represent division between RCA, LAD, and LCx and the end 
of the LM. 
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Figure 2. CTA images and volume-rendered images of the coronary arteries and the 
heart (own material)  
A: axial image of the LAD and RCA; B: coronal, multiplanar, maximal intensity 
projection image of the RCA and misalignment artifact (white arrowheads); C: curved 
multiplanar image of the RCA; D: volume-rendered 3D image of the coronary tree; E: 
volume-rendered 3D image of the heart. LAD: left anterior descending artery; LCX: left 
circumflex artery; RCA: right coronary artery  
LCX 
LAD 
RCA 
LCX 
LAD 
RCA 
A  B  C 
D  E 
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One option to eliminate vessel misalignment artifacts is reconstruction of the dataset in 
different phases of the cardiac cycle. In general coronary arteries are optimally imaged 
when the heart moves the least, which occurs in mid-diastole (during diastasis). 
However with increasing HR this period shortens, and end-systolic reconstruction 
(period of the isovolumic relaxation) might render fewer motion artifacts.  
Retrospective ECG gating provides continuous data acquisition during the cardiac cycle 
with the potential of diastolic as well as systolic image reconstruction. However 
concerns have been raised regarding the ALARA principle, which states that the 
radiation dose to a patient should be As Low As Reasonably Achievable. Currently, 
when performing cardiac CTA prospectively ECG-triggered scan protocol is preferred, 
which applies radiation only at pre-defined points of the cardiac cycle and is able to 
reduce the radiation exposure by 70 % [16]. Using this method however image 
reconstruction is limited to a pre-determined temporal-window. 
Image quality can be also substantially improved by appropriate pre-medication of 
patients with higher heart. Previous studies demonstrated that a HR of <65 bpm yielded 
the least motion artifacts [17-19]. The administration of β-blockers is commonly 
performed prior to cardiac CTA. In addition sublingual nitroglycerin is often used for 
the dilation of the coronary artery lumen thus increase the number of evaluable 
segments. The main objective of the image quality improvement is to increase the 
diagnostic accuracy of CTA for the detection of CAD. 
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1.2  Prospectively ECG-triggered image acquisition 
Radiation exposure is a major concern in coronary CTA. A multicenter (50 sites), 
observational study sought to estimate radiation dose in 1,965 patients undergoing 
coronary CTA. The median effective dose was 12 mSv [20]. Comparatively, invasive 
coronary angiography effective dose values ranges from approximately 5 to 7 mSv [21, 
22]. When interpreting coronary CTA, data is acquired with either helical (also known 
as spiral) or axial scan mode. In helical image acquisition the gantry is continuously 
rotating while the patient table smoothly moves through. In contrary during axial scan 
mode the x-ray tube and detector system must complete a full (360-degree) or partial 
(180-degree) rotation around the patient while the patient table is stationary. The table 
moves incrementally along the z-axis (also known as pitch) to collect data [23]. 
Synchronization of axial scanning with the cardiac cycle is achieved by using the ECG 
signal. During prospectively-ECG triggered or also known as “step and shoot” scan 
image acquisition is initiated after the detection of the R-peak and data is obtained 
within a predefined-phase of the R-R interval. While the table moves to the next z-axis 
position radiation exposure is suspended. This “step” then repeats until the entire heart 
is covered. Images acquired with this method can be reconstructed within a pre-
specified period of the cardiac cycle. Prospectively-ECG triggered scans permit data 
acquisition at doses of 1-6 mSv [24-26]. Newer developments on CT systems allow 
prospectively-ECG triggered helical scanning with high pitch values, thus providing 
ultra-low-dose image acquisition (<1 mSv) [27].  
In the multivendor PROTECTION III study image quality of patients with 
prospectively-ECG triggered axial scan protocol was not inferior to helical scan 
protocols (subjective image score 3.36±0.59 vs. 3.37±0.59, p=0.866), and the use of 
axial scan protocols resulted in a 70% radiation dose reduction (3.5±2.1 mSv vs. 
11.2±5.9 mSv, p<0.001) [16]. However, images obtained with this method are more 
prone to cardiac motion artifacts, therefore patients undergoing this scan technique have 
to be carefully selected. A prerequisite to achieve diagnostic image quality is the stable 
or low HR with a suggested cut-off of <65 bpm and optimally <60 bpm [6, 16, 28, 29]. 
Hence coronary CTA is customarily performed in selected patients with favorable HR 
and rhythms, and premedication is often required to induce bradycardia, usually via 
blockade of beta-adrenergic receptors.  
DOI:10.14753/SE.2017.2024
 13 
1.3 Diastolic and systolic acquisition with absolute and relative delay 
CTA image acquisitions are typically performed in the most quiescent period of the 
cardiac cycle during mid-diastole [3, 30]. While the duration of this period is relatively 
lengthy and predictable in patients with low and stable HR, at higher HRs the length of 
diastasis significantly shortens and eventually disappears [31]. Alternatively, the end-
systolic phase is the second relatively quiet phase where data acquisition is suitable 
[32]. This period is also less sensitive to R-R variability and arrhythmia as compared to 
diastole [30, 33]. For example, the length of systole shortens by 5.6 % as HRs increase 
from 80 to 90 bpm, while at the same time the length of diastole decreases by 16.4 % 
[34]. Thorough investigations have established that image reconstruction using diastolic 
data is favorable at HRs under 65 bpm [3, 4, 35], while at increased HRs, the end-
systolic and early-diastolic reconstructions are more favorable [4, 36, 37]. Furthermore, 
the length of systole is a relatively fixed phenomenon, and end-systole can be targeted 
by using absolute delay times, as opposed to defining the timing of systole as a fraction 
of the cardiac cycle.  
In cardiac CTA, several image reconstruction algorithms related to ECG signal can be 
utilized to obtain diagnostic image quality [38]. Typically images are reconstructed 
during the least motion or between T and P waves. The most frequently used approach 
is the relative delay method, in which the reconstruction starts after a certain delay from 
the prior wave which is ascribed as a certain percentage of the R-R interval. Another 
method is the absolute delay method in which reconstruction starts at a fixed time delay 
before or after the R wave and is ascribed as a specific time delay in milliseconds [39].  
Of note, comparisons of the two image reconstruction techniques have been 
infrequently investigated.   
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1.4  Premedication before coronary CTA  
Metoprolol is the IV β-blocker of choice for HR lowering in patients undergoing 
coronary CTA [7-9]. β-blockers are safe and efficacious in most patients, but 
contraindications such as reactive airway disease and hypotension are occasionally a 
serious challenge [7]. However, a previous survey revealed that 50% of centers allow an 
HR of more than 70 bpm for coronary CTA, mainly because of concerns regarding 
potential side effects of β-blocker administration [40]. The half-life of IV metoprolol is 
approximately 3 to 7 hours; therefore, if adverse effect occurs as a result of the HR-
lowering, it may debilitate the patient for hours. These data indicate the need for a safe, 
short-lasting HR control. Esmolol is a cardioselective IV β-blocker with a rapid onset 
(within 2-3 minutes) and ultrashort duration of action (mean half-life [t1/2] = 9 minutes) 
[41]. The rapid onset and offset of effects of esmolol provide an element of safety not 
previously available with longer-acting β-blockers [42].  However, no direct 
comparison between esmolol vs. metoprolol for HR control during coronary CTA is 
available.  
Nitroglycerine is frequently used alongside β-blockers for rapid dilation of the coronary 
arteries. Nitroglycerin is routinely administered to alleviate the discomfort of angina 
and has a half-life of about 5 minutes [43, 44]. The administration of sublingual 
nitroglycerin during coronary CTA improves the evaluation of coronary segments, in 
particular, in smaller coronary branches as well as provides better image quality and 
improved diagnostic accuracy. A comprehensive systematic review on the use of 
sublingual nitroglycerine in coronary CTA suggests that the optimal starting time for 
image acquisition is probably between 3 and 4 minutes after sublingual administration 
of nitroglycerin [45]. Sublingual spray is superior to the sublingual tablet as it is more 
efficacious and is associated with fewer side effects [46, 47]. The most common side 
effects are headache and dizziness, which are typically the consequence of nitrate-
induced hypotension [47, 48]. A compensatory mechanism for nitrate-induced 
hypotension is the increase of HR, which might hamper the image acquisition. 
Available data is controversial regarding HR changes after the administration of 
sublingual nitroglycerine. Some of the previous studies found no significant HR/blood 
pressure (BP) changes [49-51] while others reported substantial increase in HR [52, 53].   
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1.5  Anatomy of the aortic root 
The aortic root originates from the basal attachments of the aortic valve leaflets within 
the left ventricular outflow tract (LVOT) and extends cranially to the sinotubular 
junction. It surrounds and supports the aortic valve and functions as a transition zone 
where the ventricular structure changes into fibroelastic tissue of the aortic trunk. The 
aortic root is a geometrically complex structure, which includes the annulus, the 
semilunar aortic leaflets, the interleaflet triangles, the sinus of Valsalva, and the 
sinotubular junction [54, 55]. There are three dilations (sinuses) in the wall of the aortic 
root just superior to the semilunar leaflets. Two of the three sinuses give rise to the 
coronary arteries (Figure 3).  
Figure 3. Aortic root with aortic valve on the inside [56] 
The three valve leaflets are connected to the inner wall of the aorta creating the 
interleaflet triangles. Two of the three sinuses give rise to the origin of the left main 
(LM) and right coronary artery (RCA).  
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The annulus is not a true anatomical entity but is a virtual ring defined by the lowest 
insertion points (i.e. hinge points) of the three aortic leaflets (Figure 4).  
 
 
 
 
 
 
 
 
 
Figure 4. Aortic root with the virtual ring of the annulus [57] 
Annulus defined as a virtual ring formed by the 3 lowest insertion points (i.e. hinge 
points). 
 
When obtaining aortic root measurements with transthoracic echocardiography (TTE) 
the following dimensions are recorded: the annulus, diameter of the sinus of Valsalva, 
diameter of the sinotubular junction and diameter of the proximal ascending aorta 
(Figure 5).  
 
 
Figure 5. Aortic root measurements by TTE [58] 
1. annulus; 2. sinus of Valsalva; 3. sinotubular junction; 4. ascending aorta; LV: left 
ventricle; LA: left atrium; Ao: aorta. Dashed lines depicting the longitudinal axes of the 
LV and of the aortic root.  
LV 
1 
2  3 
4 
LA 
Ao 
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1.6  CTA for the assessment of the aortic root  
The aortic root is a complex anatomical structure therefore its 3D imaging is of 
paramount importance. CTA provides isotropic data, which can be reconstructed in any 
3D imaging plane. 
The annulus is the tightest part of the aortic root and is defined as a virtual ring formed 
by the 3 lowest points (i.e. hinge points) of the aortic leaflets as they connect to the wall 
of the LVOT [55]. A post-mortem study revealed that the shape of the annulus is not 
circular but rather oval [59]. 2D measurements (e.g. 2D TTE) of the annulus are 
therefore limited as they are based on a single plane, assuming a circular plane of the 
annulus. However, CTA-based findings are in line with autopsy findings, and suggest, 
that the annulus has an oval configuration in approximately 50% of patients evaluated 
for TAVI procedure, with a mean difference of 2.9±1.8 mm between coronal and 
sagittal views [60]. Another CTA study reported an oval shape of the annulus in 91% of 
patients [61]. These differences might be attributable to the methodology used for image 
analysis. Previously, during CTA measurement of the aortic root, short (DS) and long 
(DL) diameters of the annulus were measured on the coronal and sagittal views, which 
roughly correspond to long-axis or 3-chamber view on TTE. The disadvantage of this 
method was, that it did not provide a clearly defined plane, which is required to identify 
the true short and long diameters of the annulus. Precise diameters can be measured by 
manipulating other planes to create a double-oblique plane, which contains the 3 
insertions points. When the plane has been obtained measurement of the short and long 
diameters is necessary to calculate the mean diameter (D) of the aortic annulus: [D = 
(DL + DS)/2] [1]. The second important parameter, when measuring aortic annulus is the 
area (A) and calculation of the diameter that corresponds to this area under the 
assumption of full circularity: [D = 2√(A/π)]. The third measurement is the 
circumference (C) of the aortic annulus and calculation of the circumference-derived 
diameter: (D = C/π) [1] (Figure 6). Besides the annulus, diameter of LVOT, sinus of 
Valsalva, sinotubular junction and ascending aorta can be precisely extracted from the 
CTA dataset (Figure 7). 
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Figure 6. Assessment of the annulus dimensions by CTA (own material) 
A: the 3 lowest insertion points of the aortic leaflets (white arrows); B: long and short 
diameter (left-right white arrows) and calculated mean diameter; C: area and area-
derived diameter; D: circumference and derived diameter  
 
 
 
Figure 7. Relevant aortic root measurements by CTA (own material) 
A: CTA image of the left ventricle (LV) and aorta (Ao); B: Outline of the LV and Ao 
with other relevant aortic root measurements: 1. left ventricular outflow tract; 2. 
annulus; 3. sinus of Valsalva; 4. sinotubular juntion; 5. ascending aorta  
Short axis: 20.6 mm 
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1.7 Determinants of the aortic root geometry: genetics versus environment 
The configuration of the aortic root is determined by genetic and environmental factors 
[62-66], however their respective contributions are still unclear. Assessment of genetic 
influence might help to identify subjects predisposed to future aortic root dilation. 
Previous studies examining the heritability of the aortic root diameter using TTE 
observed moderate genetic effect [63, 67], which indicates that a major proportion of 
phenotypic variance is due to environmental factors [63].  
However, technical limitations of TTE can affect the accuracy of heritability estimates. 
Higher inter-reader variability of TTE versus CTA in the assessment of the annulus was 
previously demonstrated [68]. Furthermore, a retrospective comparison of aortic root 
dimensions by CTA and TTE demonstrated that TTE systematically underestimates the 
aortic root dimensions in patients with dilated aortic root [69]. Importantly, 
measurement errors artificially inflate the magnitude of environmental effects in 
heritability studies. Therefore, heritability estimates of the aortic root might be 
influenced by the measurement method. Precise measurements can provide more 
realistic estimates of genetic dependency.   
Heritability estimates are frequently investigated among family studies which allow for 
the estimation of the risk for the disorder in relatives. However, their drawback is that 
the estimate of risk may include both genetic and environmental influences. As twins 
share environmental factors to a unique degree [70], environmental confounders are 
minimized and the role of genetic influence can be well investigated. 
Environmental factors are also crucial in defining phenotypes. Results of the 
Framingham Heart Study concluded that age, height, weight and sex are the principal 
determinants of aortic root diameters [71]. Several investigations examined the effect of 
hypertension over the aortic root [65, 66, 71], however its association with the 
enlargement of aortic metrics is still unclear [66, 72]. A recent meta-analysis found no 
direct association between BP values and aortic root size [66]. Therefore equipoise 
remains on the impact of hypertension on aortic root dimensions.   
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2. OBJECTIVES 
2.1 Defining the optimal systolic phase targets by using absolute delay 
Coronary artery motion and deformation during cardiac cycle lead to significant motion 
artifacts when velocity of the coronaries exceeds the temporal resolution of the CT 
scanner. Furthermore, diastolic image acquisition might not be sufficient in patients 
with higher and/or variable HR. Therefore we aimed to determine the optimal systolic 
phase targets based on the velocity of the coronary arteries in patients at various HRs by 
using an absolute reconstruction delay time within the R-R interval.  
 
2.2  Defining the efficacy and safety of esmolol vs. metoprolol 
Artifact-free images are of importance for the diagnostic assessment of coronary 
arteries. Therefore adequate premedication of patients with higher HR prior to coronary 
CTA is recommended. The most common approach is the administration of IV 
metoprolol, however potential side-effects might hamper its application. Our aim was to 
investigate whether ultrashort half-life esmolol is at least as efficacious as the standard 
of care IV metoprolol for HR reduction during coronary CTA. We also sought to 
estimate the incidence of bradycardia (defined as HR <50 bpm) or hypotension (defined 
as systolic BP <100 mm Hg) as an effect of β-blockers in the esmolol and metoprolol 
groups.  
 
2.3 Defining the heritability of the aortic root by CTA and TTE  
2D and 3D imaging of the aortic root often show measurement discrepancies. 
Therefore, heritability estimates of aortic root dimensions can also vary upon the 
measurement method. We sought to assess the extent of heritability of the aortic root 
dimensions with the use of CTA in monozygotic (MZ) and dizygotic (DZ) twins. 
Furthermore, we aimed to derive TTE-based heritability estimates and compare these 
with the CTA based results. 
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3. METHODS 
3.1  Study design and study population for optimal systolic phase 
This retrospective cohort study consisted of 21 selected patients (14 men, 7 women; 
mean age 53.6 years ± 13.1; age range, 29-78 years) who were referred for clinically 
indicated coronary CTA between November 2012 and May 2013 at the Department of 
Radiology, Massachusetts General Hospital. Patient selection was based on a clinical 
decision to target a systolic image reconstruction time interval (from at least 200-420 
ms). None of the selected patients had coronary anomalies, nor had undergone coronary 
artery bypass grafting or prior electrophysiological interventions (such as ablation 
procedures, pacemaker implantation, or defibrillator implantation). Patients were 
divided into three groups based on mean HR (<65; 65-80; or >80 bpm). The mean HR 
was 71 bpm (range 52-96 bpm). The study was approved by the human research 
committee of the institutional review board (IRB), and compliance with the Health 
Insurance. A waiver of consent was obtained from our local IRB for this retrospective 
study.  
3.1.1 Coronary CTA data acquisition and image analysis  
All examinations were performed on a second-generation dual-source 128-slice CT 
scanner (SOMATOM Definition Flash, Siemens Medical Systems, Forchheim, 
Germany) with the following acquisition parameters: 128 slices at 0.6 mm thickness 
(using a z-axis flying focal spot) and gantry rotation time of 280 ms (and resultant 
temporal resolution of 75 ms). Tube potential (kilovolt-kV) and tube current 
(milliampere-second-mAs) were calculated by an automatic tube potential selection 
algorithm based on antero-posterior scout image characteristics (CAREDose 4D and 
CAREkV, Siemens) [73]. Prospectively ECG-triggered axial-sequential acquisition 
(Sequential Scanning; Siemens) with an advanced arrhythmia rejection algorithm mode 
(Adaptive Cardio Sequence, “Adaptive Cardio Sequential Flex mode”, Siemens) was 
used in 18 scans, which enabled to reject and reacquire data at table positions scanned 
during heartbeats falling outside of a pre-specified cardiac cycle length. Systolic 
acquisition was performed using an absolute delay of 200-460 ms after the R-wave with 
peak (100 % of prescribed reference) tube current from 300 to 400 ms and a baseline 
plateau (20 % of the reference tube current) in the other prescribed phases [74].  
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Three patients underwent retrospectively ECG-gated CTA with peak targets in the same 
phases of systole and with aggressive (“MinDose”, Siemens) tube modulation outside of 
the 200-460 ms window. Raw datasets were reconstructed in 20 ms increments between 
200 to 460 ms after the R peak using 1 mm thick slices and archived at the picture 
archival and communication system (PACS). Images were retrieved and displayed on a 
3D workstation (Osirix v. 3.7.1 32-bit, Pixmeo, Geneva, Switzerland). Image review 
included axial source images, orthogonal and oblique MPR images, and thin slab MIP 
images, while advancing manually through the various acquired phases in 4-
dimensional (cine) mode (Figure 8).  
 
Figure 8. Raw dataset reconstructions in 20 ms increments after the R peak [75] 
Multiple axial reconstructions of the right heart during systole (absolute delays after the 
R-wave from 180 ms through 460 ms, in 20 ms increments) demonstrate the optimal 
phase time of 340 ms at the level of the acute marginal branch (white arrow). RA: right 
atrium; LA: left atrium, AV: aortic valve; RVOT: right ventricular outflow tract  
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In patients without contraindications, 0.6 mg of sublingual nitroglycerine was 
administered approximately 5 min prior to scanning. Importantly, none of the patients 
received β-blockers during the examination, which was a decision at the discretion of 
the supervising CT physician as per standard site practice. However, 9 (43%) patients’ 
home baseline regimen included oral β-blockers.  
Arterial phase contrast was timed using the test bolus method using 20 ml iodinated 
contrast media (Iopamidol 370 g/cm3, Bracco Diagnostics Princeton, NJ USA) injected 
at a rate of 4-7 mL/s (based on body-mass index and IV access as per clinical routine) 
via an antecubital vein using a power injector. All injections were followed by a 40 ml 
of normal saline flush at a matching flow rate.  
All scans were supervised by cardiovascular imaging specialists (at least one board- 
certified or eligible radiologist or cardiologist with advanced training in cardiac CT).  
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3.1.2 Coronary artery velocity mapping  
Based on the SCCT coronary segmentation guidelines [12], six coronary artery 
landmarks, including the right coronary artery (RCA), first acute marginal branch 
(AM1), posterior descending artery (PDA), left main coronary artery (LM), first obtuse 
marginal branch (OM1), and second diagonal branch (D2) were identified in each 
patient, in 20 ms increments, by two experienced physicians. 
The end systolic phase and the end of isovolumic relaxation phases were identified with 
the aortic valve closure and initiation of mitral valve opening on the three-chamber cine 
view as demonstrated in Figure 9.  
Figure 9. Defining the end systolic phase and the end of isovolumic relaxation on three-
chamber cine view [75] 
Images were reconstructed throughout the acquired systolic intervals and they 
demonstrating the aortic (AV) and mitral (MV) valve. Aortic valve closure (black 
asterisk at 300 ms reconstruction) and the initiation of mitral valve opening (white 
asterisk at 340 ms reconstruction) can be identified, which denote the end of the systolic 
reduced ejection phase, and the end of the isovolumic relaxation, respectively.  
  
!
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Coronary artery landmark position was traced manually by placing the cursor in the 
exact center of each landmark in every phase. The x, y and z-coordinates of the selected 
landmark were then recorded (Figure 10) and were used for the calculation of the 3D 
route of coronary artery motion by using a previously established method [15]. The 
velocity of the given landmark was defined as the quotient of the route and the length of 
the time interval, which was 20 ms.  
 
Figure 10. Axial CTA image of the heart with the origin of the RCA (own material) 
X, Y and Z (white arrows) indicate the coordinates of the RCA origin and are used for 
the calculation of the coronary artery velocity  
To determine the optimal velocities in each coronary artery segment, the mean values of 
the minimum velocities were calculated separately for each HR group (i.e. <65; 65-80; 
and >80 bpm). The ideal reconstruction times in each HR group were defined as the R-
R interval with the lowest minimum mean velocity in a given segment.  
A preliminary analysis of 10 patients revealed that the mean lowest coronary artery 
velocities in each segment occurred in the middle (280-340 ms) of the selected time 
interval (200-460 ms). Therefore we divided this interval into three sections from: 200 
to 260 ms (early), 280-340 ms (mid) and 360-420 ms (late), to observe if any significant 
difference existed between the three sections.  
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3.2 Study design and population for esmolol vs. metoprolol 
Our study was a randomized single-center non-inferiority phase III clinical trial that 
compared two IV β-adrenergic receptor blockers to reduce HR in patients who 
underwent coronary CTA because of suspected CAD between April 2013 and 
September 2013 at Heart and Vascular Center, Semmelweis University. Subjects who 
had HR >65 bpm despite oral metoprolol pretreatment were enrolled in the study. 
Patients with history of a coronary intervention and an implanted stent with a diameter 
≥3 mm or previous coronary artery bypass surgery were eligible to participate in the 
study [76]. Individuals with a HR other than sinus rhythm, any contraindication against 
β-blocker (asthma bronchiale, chronic obstructive pulmonary disease, any type of 
documented atrioventricular block, severe aortic valve stenosis, severe left ventricular 
dysfunction characterized by ejection fraction below 30%), or a systolic BP <100 mm 
Hg before the coronary CTA scan were excluded from the study. In total, 650 
consecutive patients referred to coronary CTA were screened, and of these, 574 patients 
were eligible to participate in the study. In 162 patients no IV drug was administered 
because the HR before scan was ≤65 bpm. In total, 412 patients (with HR >65 bpm 
before the scan) were enrolled and randomized into either esmolol or metoprolol group; 
204 patients received IV esmolol and 208 patients received IV metoprolol (Figure 11).  
 
Figure 11. Flow chart of the study [77] 
Bpm: Beat per minute; CCTA: coronary CT angiography; IV: intravenous; HR: heart 
rate 
Patients were excluded 
4    Declined to participate 
42  Non-sinus rhythm, significant arrhythmia 
2    Atrioventricular block  
16  Asthma bronchiale  
8    Chronic obstructive pulmonary disease 
1    Severe aortic stenosis 
3    Severe left ventricular dysfunction 
76 
162 Patients with HR ≤65 bpm before CCTA 
received no IV drug 
204 Patients received IV esmolol 208 Patients received IV metoprolol 
650 Consecutive patients referred for CCTA 
574 Patients were eligable for the study 
and received oral metoprolol 
412 Patients with HR >65 bpm before CCTA  
were randomized for IV drug administration 
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3.2.1 Drug administration protocol and heart rate monitoring 
Patients received 50-mg oral metoprolol at arrival if the HR was >65 bpm. If the HR 
was ≥80 bpm, 100-mg oral metoprolol was administered. The HR was re-evaluated 
60 minutes after the oral β-blockade, immediately before the coronary CTA 
examination. Patients presenting with HR >65 bpm on the CT table were randomized to 
IV esmolol or IV metoprolol administration. In both, the investigational (esmolol) and 
the active control (metoprolol) groups, the IV drug was administered by the physician 
performing the coronary CTA scan. To achieve randomization, we administered 
esmolol on even weeks and metoprolol on odd weeks in an alternating fashion. The IV 
metoprolol (Betaloc; 1 mg/mL; AstraZeneca, Luton, United Kingdom; 5-mg ampoule) 
was titrated in 5-mg doses in every 3 minutes until the target HR (≤65 bpm) or the 
maximum dose of metoprolol (20 mg) was achieved [78]. 
The esmolol (Esmocard; 2500 mg/10 mL; AOP Orphan Pharmaceuticals AG, Vienna, 
Austria) was diluted to 500 mg/10 mL and titrated in ascending 100-, 200-, 200-mg 
doses in every 3 minutes until the target HR (≤65 bpm) or the maximum dose of 
esmolol (500 mg) was achieved. BP was monitored before every administered drug 
bolus. If hypotension (defined as systolic BP <100 mm Hg) or bradycardia (defined as 
HR <50 bpm) was measured, the administration of the β-blocker agent was suspended. 
Two puffs of sublingual nitroglycerine were given to each patient 3 to 5 minutes before 
the CT scan to ensure the proper visualization of the coronaries. The HR was recorded 
at arrival (T1), immediately before coronary CTA (T2), during breath-hold, contrast 
injection, and scan (TS), immediately after scan (T3), and 30 minutes after coronary 
CTA scan (T4). BP was measured at T1, T2, T3, and T4 time points.  
We have performed an interim analysis after 45 days to ensure adequate enrollment rate 
and to assess toxicity as well as adverse events. An adverse event was defined as a 
change in health condition resulting from the administration of β-blockers, which is not 
resolving with observation and requires medical intervention. 
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3.2.2 Coronary CTA scan protocol 
CTA examinations were performed using a 256-slice multidetector-row CT (Brilliance 
iCT, Philips HealthTech, Best, The Netherlands) with the following acquisition 
parameters: 128 mm×0.625 mm collimation, 270 ms rotation time, 80-120 kV tube 
voltage, 150-300 mAs tube current depending on the patients’ body mass index (BMI). 
Contrast-enhanced images were acquired using prospective ECG triggering at 75% to 
81% phase (3% padding). The iodinated contrast agent (Iomeron 400; Bracco Ltd, 
Milan, Italy) was injected into an antecubital vein via an 18-ga cannula using a dual-
syringe technique, at a flow rate of 3.5 to 5.5 mL/s depending on patients’ BMI and the 
tube voltage. Bolus tracking was performed using a region of interest in the left atrium. 
Images were reconstructed with a slice thickness of 0.8 mm and 0.4 mm increment. CT 
datasets were analysed offline on workstations equipped with dedicated cardiac post-
processing software (Intellispace Portal, Philips HealthTech).  
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3.3 Study design and population for heritability of the aortic root  
Our study population consisted of 202 twins (61 monozygotic (MZ), 40 dizygotic (DZ) 
same-sex pairs), who were enrolled in the BUDAPEST-GLOBAL (Burden of 
atherosclerotic plaques study in twins - Genetic Loci and the Burden of Atherosclerotic 
Lesions) clinical study between April 2013 and July 2014, at Heart and Vascular 
Center, Semmelweis University. Detailed description of the study protocol has been 
published previously [79]. Briefly, the BUDAPEST-GLOBAL study is a prospective, 
single-center, classical twin study that sought to evaluate the influence of genetic and 
environmental factors on the burden of CAD. Participants with self-reported Caucasian 
ethnic background were enrolled from the Hungarian Twin Registry on a voluntary 
basis [80]. Two twin pairs were excluded from the CTA analysis due to insufficient 
image quality (one pair) and withdrawal of study consent (the other pair), while eight 
twin pairs were excluded from TTE analysis due to the poor quality of the acquired 
images. No subjects were excluded for the presence of severe valve disease. In total, 
198 twin subjects were analysed by CTA and 186 by TTE. Complete physical 
examination and anthropometric measurements were performed in all participants, 
which included the recording of waist circumference, height and weight as well as the 
calculation of the BMI. Brachial blood pressure values were recorded prior to CTA. 
Traditional cardiovascular risk factors such as hypertension, diabetes mellitus, 
dyslipidaemia and smoking habits were collected from patients’ medical history. All 
participants provided informed consent. The investigation was approved by the National 
Research Ethics Committee (IRB number 58401/2012/EKU [828/PI/12]; amendment: 
12292/2013/EKU) and was conducted according to the principles stated in the 
Declaration of Helsinki.   
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3.3.1 CTA scan and drug administration protocol  
All CTA examinations were performed using a 256-slice multidetector-row CT 
(Brilliance iCT, Philips HealthTech, Best, The Netherlands) with the following 
acquisition parameters: 128 mm×0.625 mm collimation, 270 ms rotation time, 100-120 
kV tube voltage, 200-300 mAs tube current depending on the patients’ BMI. Contrast-
enhanced images were acquired using prospective ECG triggering at 78% phase (3% 
padding). If the initial heart rate of the participants was >65 bpm, oral (maximum dose 
of 100 mg) or intravenous (maximum dose of 20 mg) metoprolol was administered. 
Subjects received 0.8 mg of sublingual nitroglycerin, no more than 2 minutes before 
image acquisition. Triphasic contrast injection protocol was performed using 80 mL of 
iodinated contrast agent (Iomeprol 400 g/cm3, Iomeron, Bracco Imaging S.p.A., Milano, 
Italy), mixture of contrast agent and saline (10 mL contrast agent and 30 mL saline) and 
a chaser of 40 mL saline, all injected with a flow rate of 4.5-5.5 ml/s into an antecubital 
vein. Bolus tracking was performed using a region of interest in the left atrium. Images 
were reconstructed with a slice thickness of 0.8 mm and 0.4 mm increment. CT datasets 
were analysed offline on workstations equipped with dedicated cardiac post-processing 
software (Intellispace Portal, Philips HealthTech). 
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3.3.2 CTA analysis of the aortic root 
The following diameters were measured by a single reader (CC, with three years of 
experience): left ventricular outflow tract (LVOT), annulus, sinus of Valsalva, 
sinotubular junction and ascending aorta (Figure 12).  
 
Figure 12. CTA-based aortic root measurements [81] 
A: coronal CTA image of the left ventricle (LV), right ventricle (RV) and aortic root; B: 
3D volume rendered image of the aortic root and the left ventricular cavity. White lines 
correspond to measured aortic root diameters: 1. left ventricular outflow tract; 2. 
annulus; 3. sinus of Valsalva; 4. sinotubular junction; 5. ascending aorta; LM: left main 
coronary artery; RCA: right coronary artery 
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By using a semi-automated software tool (Intellispace Portal, Philips HealthTech) 
modified orientation views similar to those used for TAVI procedures were acquired for 
the initial evaluation of the aortic root [1]. The axial plane was automatically aligned 
with the lowest insertion points of the 3 coronary cusps (Figure 13). In case of 
misalignment manual correction of the insertion points was performed. Based on the 
annulus-plane diameters of the LVOT, annulus, sinus of Valsalva, sinotubular junction 
and ascending aorta were obtained by the software. The diameter of a given structure 
was defined as the mean of the short and long axis [1]. To assess intra-reader 
reproducibility the same reader performed the previously described measurements in 20 
twin pairs. For inter-reader reproducibility, another experienced reader (MK, with five 
years of experience) also measured the diameters of the aortic root. All measurements 
were performed blinded to the zygosity of twins. 
 
Figure 13. Axial plane of the annulus on CTA (own material) 
Annulus defined by the three lowest insertion points (right coronary cusp, left coronary 
cusp and non-coronary cusp). An: annulus; LA: left atrium; RA: right atrium; RV: right 
ventricle; RCA: right coronary artery  
Le  coronary 
cusp 
Non-coronary 
cusp 
Right coronary 
cusp 
LA 
RA 
RV 
An 
RCA 
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3.3.3 TTE imaging of the aortic root 
Two-dimensional TTE was performed using iE33 system, S5-1 transducer (Philips 
Healthcare, Best, The Netherlands). Aortic root measurements were obtained by one 
experienced operator (AK, with three-years of experience), who was blinded to the 
zygosity of the twins and the CTA exams. Standard two-dimensional protocol was used 
according to current guidelines [58]. Parasternal long-axis views were acquired to 
measure the LVOT and aortic root at the level of the annulus, sinus of Valsalva, 
sinotubular junction and ascending aorta using the inner edge to inner edge method 
(Figure 14) [58]. The LVOT and the annulus were measured in zoom mode. Diameters 
of the LVOT and annulus were assessed on a mid-systolic frame, all other parameters 
on end-diastolic frame [58]. All recordings included 3 cardiac cycles and were exported 
to a workstation for off-line analysis (Image-Com, TomTec Imaging Systems, 
Unterschleissheim, Germany). To assess intra-reader reproducibility the same reader 
performed the previously described measurements in 20 twin pairs. For inter-reader 
reproducibility, another experienced reader (AAM, with eight years of experience) also 
measured the diameters of the aortic root. Inter-modality agreement between CTA and 
TTE was also calculated.  
Figure 14. TTE-based aortic root measurements [81] 
A: zoomed parasternal long-axis view at mid-systolic frame of the aortic root; B: 
optimized parasternal long-axis view at end-diastolic frame of the aortic root; Inner 
edge to inner edge method was applied. White lines correspond to measured aortic root 
diameters: 1. left ventricular outflow tract; 2. annulus; 3. sinus of Valsalva; 4. 
sinotubular junction; 5. ascending aorta  
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3.4  Statistical analyses  
Continuous variables were reported as mean ± standard deviation (SD) or median 
(interquartile range) for non-normally distributed data. Categorical variables are given 
as frequency (%). Normal distribution was tested using the Shapiro-Wilk tests. Non-
parametric data was analyzed using robust t tests using 20%-trimmed means with 
bootstrapping or when data was very skewed applying a Mann–Whitney-U test. 
Differences of categorical variables between treatment groups were analyzed by chi-
square tests.  Correlations were calculated with Pearson’s correlation test or Spearmans 
rho test as appropriate. To compare multiple variables one-way ANOVA, followed by 
Bonferroni post hoc test, or Kruskal–Wallis ANOVA followed by Mann–Whitney-U 
test was used depending on normality. Within subjects, measurements were compared 
using repeated measures ANOVA. A P-value of <0.05 was considered significant. 
Statistical analyses were performed with R, version 3.0.2 (R Foundation for Statistical 
Computing, Vienna, Austria).  
 
3.4.1 Sample size calculation for the esmolol vs. metoprolol study 
The sample size calculation to determine the efficacy and safety of esmolol was based 
on prior research, which showed that 83% of patients who received metoprolol 
premedication achieved a HR of ≤65 bpm [82]. The non-inferiority margin was set to 
10% because we have assumed that this is a clinically acceptable maximum difference 
between the responder proportions of the two treatment groups. Thus, our primary aim 
to achieve at least 73% responder proportion seemed to be realistic. A total of 595 
patients, 297/298 patients on each treatment arm, were needed to find a difference 
between proportions of responders in metoprolol group vs. esmolol group. The sample 
size calculation was based on an intention to treat analysis using a non-inferiority 
margin set at 10% with a power of 90%. Dedicated software was used for sample size 
calculation (East, version 5.4.1; Cytel Inc, Cambridge, Massachusetts).  
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3.4.2 Statistical analysis for heritability estimates 
Based on CTA and TTE measurements we determined co-twin correlations between 
MZ and DZ twins. In addition to correlation-based similarities a structural equation 
model, the ACDE model was used to decompose the total variance between twins. In 
the ACDE model four latent variables: additive genetic (A), common environmental 
(C), dominant genetic (D) and unique environmental (E) effects drive the variance of 
phenotype in each twin. Since C and D factors are confounded only models calculating 
with C or D, next to A and E can be used. Additive genetic effects (A) are perfectly 
(1.0) correlated across MZ twins and 0.5 correlated across DZ twins. Common 
environmental effects (C) are perfectly correlated within twin pairs independently of 
zygosity. Unique environmental effects (E) are uncorrelated within co-twins (Figure 
15). Since measurement error in the phenotype is also uncorrelated across 
measurements, it appears as part of the unique environmental (E) component.  
 
Figure 15. ACE model (own material) 
Additive genetic effects (A) are perfectly (1.0) correlated across MZ twins and 0.5 
correlated across DZ twins. Common environmental effects (C) are perfectly correlated 
within twin pairs independently of zygosity. Unique environmental effects (E) are 
uncorrelated within twins. Additive genetic effects (A) and common environmental 
effects (C) increase, while unique environmental effects (E) decrease the similarity 
between twins. P: phenotype  
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Statistical analyses were done using the R environment (version: 3.2.1) [83]. Two-
sample t-test and chi-square test was used to assess differences between the measured 
parameters of MZ and DZ twins. Paired t-test was used to evaluate the differences 
between aortic parameters measured by CTA and TTE. Intra-and inter-reader variability 
was assessed using the intraclass correlation coefficient (ICC) using IRR package 
(version: 0.84) [84].  
Structural equation modelling was used to decompose sources of variation using 
univariate ACDE models using the OpenMx package (version: 2.2.4) [85, 86]. Total 
variation between twins is considered to be a product of additive genetic (A), common 
environmental (C), dominant genetic (D) and unique environmental (E) effects. All 
factors cannot be simultaneously estimated since C and D are confounded due to 
statistical power issues, thus ACE and ADE models were calculated separately. 
Potential covariates were selected using all subset regression analysis using the leaps 
package (version: 2.9) [87]. Based on the results age, sex, height and diastolic blood 
pressure were included as covariates. Akaike Information Criterion (AIC) and Bayesian 
Information Criterion (BIC) were used to determine the most parsimonious model 
among calculated full models. Likelihood ratio test was used to assess the fit of the 
submodels compared to corresponding full models. In case the fit did not decrease 
significantly, the more parsimonious submodel was selected. Bootstrapped confidence 
intervals (CI) of all modelled parameters were calculated using 2000 iterations to 
achieve robust results.  
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4. RESULTS 
4.1 Optimal systolic phase targets by using absolute delay 
To define the optimal systolic phase targets at patients with various HR, we analyzed a 
total of 1488 coronary artery landmarks (24 of the various landmark data points were 
deemed non-evaluable or missing), in 21 patients at 6 locations throughout the coronary 
artery tree, at 12 time-points throughout the systolic phase reconstructions.  
Overall, no correlation was found between coronary artery velocities and HR (RCA: r=-
0.08, p=0.75; AM1: r=-0.48, p=0.03; PDA: r=-0.31, p=0.17; LM: r=-0.14; p=0.54; 
OM1: r=-0.17, p=0.45; D2: r=-0.16, p=0.48). Table 1 lists the minimal velocities in 
millimeter/second (mm/s) in each segment for each HR group. No differences were 
found in the minimal coronary artery velocities between the three HR groups, with the 
exception of the AM1 branch (p=0.005) between <65 vs. >80 bpm (p=0.03), and at HRs 
of 65-80 vs. >80 bpm (p=0.006). 
 
Table 1. Minimal velocities across the coronary arteries in mm/s in each HR group [75]  
RCA: right coronary artery; AM1: first acute marginal branch;   PDA: posterior 
descending artery; LM: left main coronary artery; OM1: first obtuse marginal branch; 
D2: second diagonal branch 
  <65 65-80 >80 All p 
RCA 14.2 12.4 12.6 13.1 0.880 
AM1 19.5 21.9 9.4 16.9 0.005 
PDA 22.1 15.8 15.0 17.7 0.413 
LM 12.9 11.9 11.5 12.1 0.940 
OM1 14.0 13.8 11.8 13.2 0.774 
D2 14.1 12.6 12.7 13.1 0.884 
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Table 2 shows the optimal systolic phase reconstruction times of the evaluated coronary 
artery segments in milliseconds (ms). Significant differences in optimal reconstruction 
time points were detected only in the RCA (p=0.019) between HR of 65-80 bpm vs. 
>80 bpm.  
 
Table 2. Optimal systolic phase reconstruction time in ms in each HR group  
RCA: right coronary artery; AM1: first acute marginal branch; PDA: posterior 
descending artery; LM: left main coronary artery; OM1: first obtuse marginal branch; 
D2: second diagonal branch 
  <65 65-80 >80 All p 
RCA 326 357 269 317 0.019 
AM1 343 311 334 329 0.451 
PDA 326 274 277 292 0.177 
LM 300 263 257 273 0.249 
OM 311 343 289 314 0.294 
D2 277 306 303 295 0.542 
 
 
Tables 1 and 2 indicate that coronary artery minimal velocities and optimal time-points 
are independent of HR. However, note that in two segments (AM1 and RCA) 
significant differences were demonstrated. 
A preliminary analysis of ten patients revealed that the mean lowest coronary artery 
velocities in each segment occurred in the mid period (280-340 ms) of the acquired 
systolic phase (200-420 ms). Therefore we divided this interval into three time-periods 
from: 200 to 260 ms (early), 280-340 ms (mid) and 360-420 ms (late), to evaluate 
potential differences. The analysis of all 21 patients’ mean velocities in each of the three 
time periods confirmed this observation. In the mid period, (280-340 ms) in each 
coronary segment, the mean velocity values were significantly lower versus the early 
and/or late phases of the selected time interval (Table 3, Figure 16). In the LM, OM1 
and D2, a significant difference was also found between the early and late time periods. 
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Table 3. Differences between the systolic phase targets  
RCA: right coronary artery; AM1: first acute marginal branch; PDA: posterior 
descending artery; LM: left main coronary artery; OM1: first obtuse marginal branch; 
D2: second diagonal branch  
Coronary artery 
 segment 
Time interval 
(ms) 
Mean 
velocity 
(mm/s) 
 
p-value 
p between 
time 
intervals 
RCA  early (200 - 260) 48.4   
 mid   (280 - 340) 44.6  mid vs. late  
p=0.005  late   (360 - 420) 58.9  
   p=0.005  
AM1 early (200 - 260) 75.0  mid vs. early 
p=0.004  mid   (280 - 340) 54.0  
 late   (360 - 420) 66.4   
   p=0.005  
PDA early (200 - 260) 79.2  mid vs. early 
p=0.016  mid   (280 - 340) 51.5  
 late   (360 - 420) 95.6  mid vs. late  p<0.001 
    p<0.001  
LM early (200 - 260) 41.4 
 
early vs. late 
p=0.003 
 mid   (280 - 340) 41.1  mid vs. late 
p<0.002  late   (360 - 420) 53.8  
   p<0.001  
OM1 early (200 - 260) 48.4 
 
early vs. late 
p=0.002 
 mid   (280 - 340) 42.9  mid vs. late 
p<0.001  late   (360 - 420) 70.2  
   p<0.001  
D2 early (200 - 260) 42.0 
 
early vs. late 
p=0.007 
 mid   (280 - 340) 42.6  mid vs. late  
p=0.010  late   (360 - 420) 56.0  
   p=0.003  
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Figure 16. Mean coronary artery velocities in each of the three time periods [75] 
The lowest coronary velocity was detected in the mid period (280-340 ms) of the 
reconstructed interval (200-420 ms). The mean velocities in this period were 
significantly lower than in the early and/or late periods.  
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4.2  Efficacy and safety of esmolol vs. metoprolol 
Patient enrollment was terminated as early as the interim analysis indicated that IV 
esmolol is clearly non-inferior to IV metoprolol, and in fact, esmolol showed superior 
characteristics compared to IV metoprolol in reducing HR during coronary CTA.  
There was no difference between the esmolol and metoprolol group regarding the 
clinical characteristics of patients (Table 4).  
 
Table 4. Demographic characteristics of the study groups [77]  
AMI: acute myocardial infarction; BMI: body mass index; CABG: coronary artery 
bypass graft; PAD: peripheral arterial disease; PCI: percutaneous coronary intervention; 
mean values r SD 
 
 
esmolol 
(n=204)  
metoprolol 
(n=208) p 
age (years)  56.9 r 10.8  57.6 r 12.2 0.390 
male/female 100/104  111/97 0.377 
BMI (kg/m2) 28.4 r 4.9  28.2 r 4.7 0.956 
hypertension (%) 67  66 0.889 
diabetes (%) 16  14 0.603 
dyslipidemia (%) 48  55 0.154 
AMI (%) 5  10 0.076 
PCI (%) 5  7 0.455 
CABG (%) 4  6 0.287 
PAD (%) 9  8 0.801 
stroke (%) 4  1 0.072 
smoking (%) 25  26 0.845 
β -blocker (%) 47  48 0.795 
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In the esmolol group, 53 of 204 patients (26.0%) received 1 bolus (100 mg), 73 of 204 
(35.8%) received 2 boluses (300 mg), and 78 of 204 (38.2%) received 3 boluses 
(500 mg) of esmolol. In the metoprolol group, IV metoprolol was administered in a 
similar fashion as in the esmolol group but in 5-mg increments. Eighty-three of 208 
patients (39.9%) received 1 bolus (5 mg), 45 of 208 patients (21.6%) 2 boluses (10 mg), 
53 of 208 (25.5%) 3 boluses (15 mg), and 27 of 208 (13.0%) 4 boluses (20 mg) of 
metoprolol. Oral metoprolol administration was similar in the esmolol and metoprolol 
groups (51.2 ± 33.1 vs. 52.4 ± 33.6; p=0.71). On average, 325.6 ± 158.4 mg IV esmolol 
and 10.7 ± 6.3 mg IV metoprolol were administered. The mean HR of the esmolol and 
metoprolol groups was similar at the time of arrival (T1: 78 ± 13 vs. 77 ± 12 
bpm; p=0.65) and immediately before the coronary CTA examination (T2: 68 ± 7 vs. 69 
± 7 bpm; p=0.60). However, HR during the scan was significantly lower among the 
patients who received IV esmolol vs. patients who received IV metoprolol (TS: 58 ± 6 
vs. 61 ± 7 bpm; p<0.0001). On the other hand, HR immediately after the coronary CTA 
and 30 minutes after the coronary CTA was higher in the esmolol group than in the 
metoprolol group (T3: 68 ± 7 vs. 66 ± 7 bpm; p<0.01; and T4: 65 ± 8 vs. 63 ± 8 
bpm; p<0.0001, respectively; Table 5, Figure 17). Systolic and diastolic BP showed no 
difference between the 2 groups measured at any time point (Table 6). 
 
Table 5. Mean HR in the esmolol and metoprolol group  
T1: arrival; T2: before scan; TS: during scan; T3: after scan; T4: emission; mean values 
r SD 
 
esmolol 
(n=204)  
metoprolol 
(n=208) p 
T1 78 r 13  77 r 12 0.652 
T2 68 r 7  69 r 7 0.599 
TS 58 r 6  61 r 7 <0.0001 
T3 68 r 7  66 r 7 <0.01 
T4 65 r 8  63 r 8 <0.0001 
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Figure 17. Mean HR in the esmolol and metoprolol group [77] 
The figure represents the mean HR and their standard deviations in the esmolol and 
metoprolol groups at different time points. The red triangles represent the mean HR in 
the esmolol group, whereas the black squares indicate the mean HR in the metoprolol 
group. T1: time of arrival; T2: time point before the coronary CT angiography (CTA) 
scan; TS: during the coronary CTA scan; T3: time point immediately after the coronary 
CTA; T4: 30 minutes after the coronary CTA. *p<0.01; ***p<0.0001.  
 
Table 6. Blood pressure in mm Hg in the esmolol and metoprolol group  
T1: arrival; T2: before scan; T3: after scan; T4: emission; mean values r SD 
 
esmolol 
(n=204)  
metoprolol 
(n=208) p 
T1     systole 142 r 22  146 r 21 0.195 
diastole 87 r 12  87 r 12 0.819 
T2     
systole 144 r 21  145 r 20 0.918 
diastole 86 r 13  87 r 12 0.945 
T3     
systole 128 r 20  131 r 19 0.053 
diastole 74 r 12  75 r 12 0.522 
T4     
systole 132 r 20  134 r 21 0.414 
diastole 79 r 11  80 r 12 0.589 
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HR of ≤65 bpm was reached in 182 of 204 (89%) patients in the esmolol group vs. in 
162 of 208 (78%) patients in the metoprolol group (p<0.05), whereas HR ≤60 bpm was 
reached in 147 of 204 (72%) patients who received esmolol vs. in 117 of 208 (56%) 
patients who received metoprolol (p<0.001; Figure 18).  
 
Figure 18. Proportions of patients who achieved the target HR [77] 
The bar charts illustrate the proportion of patients who reached a HR ≤60 bpm and the 
proportion of patients who reached a HR ≤65 bpm in the esmolol and metoprolol 
groups. 
None of the patients developed bradycardia (defined as HR <50 bpm) after β-blocker 
administration (minimum HR in the esmolol group was 53 bpm; minimum HR in the 
metoprolol group was 52 bpm). However, hypotension (defined as systolic BP 
<100 mm Hg) was observed in 19 patients (9.3%) in the esmolol group and in 8 patients 
(3.8%) in the metoprolol group right after the scan (T3; p <0.05). Importantly, only 5 
patients (2.5%) had a systolic BP <100 mmHg 30 minutes after the scan (T4) in the 
esmolol group, whereas the number of patients with hypotension remained 8 (3.8%) in 
the metoprolol group (p=0.418). None of the patients required hospitalization or 
medical intervention due to hypotension and the systolic BP normalized after a short 
(maximum 2 hours) observation in every case. Of note, the absolute time spent in the 
CT unit (T2-T3) did not differ between the esmolol and metoprolol group (21.1 ± 7.5 
vs. 21.8 ± 7.9 minutes; p=0.428).  
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4.3 Heritability estimates of aortic root dimensions by CTA and TTE 
This study consisted of 198 twins (118 MZ, 80 DZ; mean age for MZ 54.5 ± 9.7 and DZ 
58.3 ± 8.4 years; 126 female) who prospectively underwent both CTA and TTE. Patient 
characteristics are provided in detail in Table 7. No significant differences were found 
between MZ and DZ twins except for age (p=0.004). CTA and TTE-derived diameters 
as well as inter-modality differences are shown in Table 8. 
 
Table 7. Demographic characteristics of the study population [81] 
Continuous variables are presented as mean values ± SD, while categorical as n (%). p 
values represent statistical tests done between the MZ and DZ subgroups. BMI: Body 
Mass Index; SBP: Systolic Blood Pressure; DBP: Diastolic Blood Pressure; HT: 
Hypertension; DM: Diabetes Mellitus; DLP: Dyslipidaemia; MZ: monozygotic twins; 
DZ: dizygotic twins 
 
Total 
(n = 198) 
MZ 
(n = 118) 
DZ 
(n = 80) 
p 
Female (n) 126 (63.6%) 70 (59.3%) 56 (70.0%) 0.13 
Age (y) 56.1 ± 9.4 54.5 ± 9.7 58.3±8.4 0.004 
Waist (cm) 97.1 ± 14.1 96.8 ± 14.4 97.5 ± 13.7 0.73 
Height (cm) 166.4 ± 9.7 166.4 ± 10.1 166.5 ± 9.0 0.98 
Weight (kg) 77.4 ± 17.3 77.5 ± 17.9 77.1 ± 16.4 0.87 
BMI (kg/m2) 27.8 ± 5.3 27.8 ± 5.0 27.9 ± 5.8 0.93 
SBP (mmHg) 139.4 ± 20.4 138.4 ± 19.4 141.0 ± 21.7 0.38 
DBP (mmHg) 85.7 ± 12.4 85.2 ± 12.5 86.5 ± 12.3 0.50 
HT (n) 83 (41.9%) 46 (39.0%) 37 (46.3%) 0.31 
DM (n) 18 (9.1%) 12 (10.2%) 6 (7.5%) 0.52 
DLP (n) 83 (41.9%) 44 (37.3%) 39 (48.8%) 0.11 
Current smoker (n) 29 (14.6%) 17 (14.4%) 12 (15.0%) 0.91 
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Table 8. Aortic root diameter measurements in millimetres (mm) as assessed by computed tomography angiography and transthoracic 
echocardiography  
CTA: computed tomography angiography; TTE: transthoracic echocardiography; LVOT: left ventricular outflow tract 
 
 CTA TTE Inter-modality 
Variable (mm) Total 
(n = 198) 
MZ 
(n = 118) 
DZ 
(n = 80) 
p Total 
(n = 186) 
MZ 
(n = 108) 
DZ 
(n = 78) 
p p 
LVOT  23.2 ± 2.4 23.2 ± 2.5 23.3 ± 2.2 0.92 18.9 ± 2.3 18.9 ± 2.4 18.9 ± 2.2 0.99 <0.001 
Annulus  23.4 ± 2.1 23.3 ± 2.2 23.5 ± 1.9 0.43 19.7 ± 2.4 19.8 ± 2.3 19.5 ± 2.5 0.52 <0.001 
Sinus of Valsalva  32.8 ± 3.6 32.7 ± 3.4 32.9 ± 3.7 0.69 33.0 ± 5.1 33.5 ± 5.3 32.3 ± 4.7 0.11 0.34 
Sinotubular junction  28.2 ± 3.1 27.9 ± 2.9 28.7 ± 3.4 0.07 25.5 ± 3.3 25.1 ± 3.3 26.1 ± 3.4 0.05 <0.001 
Ascending aorta  30.5 ± 3.6 30.2 ± 3.4 30.9 ± 3.6 0.13 30.7 ± 3.9 30.5 ± 3.9 31.0 ± 4.0 0.41 0.12 
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Both CTA- and TTE-measured diameters were similar between MZ and DZ twins. In 
terms of inter-modality, CTA and TTE-derived parameters were significantly different 
regarding LVOT, annulus, and sinotubular junction (all p<0.001), however, the 
diameter of the sinus of Valsalva and ascending aorta were similar (p=0.34; p=0.12, 
respectively). The intra-reader reproducibility of both CTA (range: 0.98-0.99) and TTE 
(range: 0.96-0.99) was excellent. The inter-reader reproducibility was lower for all 
aortic measurements using TTE (range: 0.58-0.94) compared to CTA (range: 0.94-
0.99). The intra- and inter-reader reproducibility results are summarized in Table 9. 
 
Table 9. Inter-reader and intra-reader intraclass correlation coefficient results by 
imaging modality  
Confidence intervals (CI) are shown in parenthesis. CTA: computed tomography 
angiography; TTE: transthoracic echocardiography; ICC: Intraclass correlation 
coefficients 
 CTA TTE 
Variable Inter-reader ICC (95% CI) 
Intra-reader 
ICC (95% CI) 
Inter-reader 
ICC (95% CI) 
Intra-reader 
ICC (95% CI) 
LVOT 0.99 (0.97 - 0.99) 0.99 (0.97 - 0.99) 0.59 (0.35 - 0.76) 0.98 (0.97 - 0.99) 
Annulus 0.94 (0.89 - 0.97) 0.99 (0.97 - 0.99) 0.58 (0.33 - 0.75) 0.96 (0.94 - 0.98) 
Sinus of Valsalva 0.99 (0.98 - 0.99) 0.99 (0.99 - 1.00) 0.88 (0.79 - 0.93) 0.97 (0.94 - 0.98) 
Sinotubular 
junction 
0.95 (0.92 - 0.98) 0.98 (0.97 - 0.99) 0.77 (0.61 - 0.87) 0.96 (0.92 - 0.97) 
Ascending aorta 0.99 (0.98 - 0.99) 0.99 (0.98 - 1.00) 0.94 (0.90 - 0.97) 0.99 (0.97 - 0.99) 
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Co-twin correlations were calculated regarding the aortic root measurements for MZ 
and DZ twins (Table 10). Higher intra-pair correlation values were observed in the MZ 
twins compared to DZ twins with both imaging modalities, however differences 
between the correlation values were higher using CTA-based measurements. 
 
Table 10. Correlation coefficient values of MZ and DZ twins measured aortic root 
diameters using computed tomography and echocardiography  
rMZ: Co-twin Pearson correlation coefficient among MZ twins; rDZ: Co-twin Pearson 
correlation coefficient among DZ twins; CTA: computed tomography angiography; 
TTE: transthoracic echocardiography; LVOT: left ventricular outflow tract 
 CTA TTE 
Variable rMZ rDZ rMZ rDZ 
LVOT 0.89 0.60 0.51 0.46 
Annulus 0.90 0.58 0.60 0.59 
Sinus of Valsalva 0.91 0.69 0.67 0.65 
Sinotubular junction 0.88 0.52 0.65 0.50 
Ascending aorta 0.84 0.47 0.76 0.54 
Structural equation modelling was used to decompose the total variance between the 
twins to genetic and environmental components. Models were adjusted for age, sex, 
height and diastolic blood pressure based on linear regression results. For all CTA-
derived parameters, ADE models had better fit compared to ACE models based on AIC 
and BIC values. Even though ADE models were selected based on CTA measurements, 
the dominant genetic component was dropped out in all cases based on likelihood ratio 
tests, resulting AE models for all parameters (LVOT: A=0.67, E=0.33; annulus: 
A=0.76, E=0.24; sinus of Valsalva: A=0.83, E=0.17; sinotubular junction: A=0.82, 
E=0.18; ascending aorta: A=0.75, E=0.25). Interestingly, in case of TTE-derived 
measurements, ACE models showed a better fit as compared to ADE models in all 
cases. LVOT and ascending aorta parameters resulted in AE models while annulus, 
sinus of Valsalva and sinotubular junction resulted in CE models based on likelihood 
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ratio tests (LVOT: A=0.38, E=0.62; annulus: C=0.47, E=0.53; sinus of Valsalva: 
C=0.63, E=0.37; sinotubular junction: C=0.45, E=0.55; ascending aorta: A=0.67, 
E=0.33). Results are represented in Figure 19 and detailed statistics are available in 
Table 11 and 12.  
 
Figure 19. Heritability estimates of aortic root parameters using CTA and TTE [81] 
In case of CTA-based measurements, AE models were most parsimonious, which 
suggests a strong genetic determination of the aortic metrics. TTE-derived 
measurements showed AE models for ascending aorta and LVOT and CE models for 
sinotubular junction, sinus of Valsalva and annulus, which suggests moderate to no 
genetic influence on the aortic root.  
CTA: computed tomography angiography; TTE: Transthoracic echocardiography; A: 
additive genetic effects; C: common environmental effects; E: unique environmental 
effects; LVOT: left ventricular outflow tract 
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Table 11. Detailed results of structured equation models (ACE and ADE) for aortic root diameters measured by CTA 
Bootstrapped confidence intervals are represented in parenthesis. * indicates most parsimonious full model based on AIC and BIC values.  
† indicates most parsimonious submodel based on likelihood difference test. A: additive genetic effects; C: common environmental effects; 
D: dominant genetic effects; E: unique environmental effects; -2LL: minus 2 log-likelihood values; AIC: Akaike information criterion; 
BIC: Bayesian information criterion; df: degrees of freedom 
 
 
Variable Full model 
Estimated 
parameters A C or D E -2LL 
Difference 
to 
Saturated 
model 
 -2LL 
Likelihood 
ratio test  
p 
AIC BIC 
Difference 
to Full 
model  
-2LL 
Difference 
to Full 
model  
df 
Difference 
to Full 
model  
p 
LVOT ACE ACE 0.68 (0.26 - 0.80) 0.00 (0.00 - 0.37) 0.32 (0.20 - 0.51) 714.83 17.80 0.01 334.83 158.24       AE 0.68 (0.50 - 0.80)  0.32 (0.20 - 0.50) 714.83 17.80 0.01 332.83 162.84 0.00 1 1.00    CE  0.54 (0.35 - 0.67) 0.46 (0.33 - 0.64) 725.42 28.38 <0.001 343.42 152.25 10.58 1 <0.001    E   1.00 (1.00 - 1.00) 758.46 61.43 <0.001 374.46 123.80 43.63 2 <0.001   ADE* ADE 0.00 (0.00 - 0.73) 0.68 (0.00 - 0.80) 0.32 (0.20 - 0.48) 713.35 16.32 0.01 333.35 159.72       
   AE† 0.67 (0.50 - 0.80)  0.33 (0.21 - 0.50) 714.83 17.80 0.01 332.83 162.84 1.48 1 0.22 
   E   1.00 (1.00 - 1.00) 758.46 61.43 <0.001 374.46 123.80 45.11 2 <0.001 Annulus ACE ACE 0.76 (0.60 - 0.85) 0.00 (0.00 - 0.00) 0.24 (0.15 - 0.38) 647.55 11.20 0.08 267.55 225.52       
   AE 0.76 (0.60 - 0.85)  0.24 (0.15 - 0.40) 647.55 11.20 0.13 265.55 230.11 0.00 1 1.00    CE  0.55 (0.34 - 0.68) 0.45 (0.32 - 0.66) 667.10 30.75 <0.001 285.10 210.57 19.55 1 <0.001    E   1.00 (1.00 - 1.00) 701.58 65.23 <0.001 317.58 180.68 54.02 2 <0.001   ADE* ADE 0.00 (0.00 - 0.66) 0.76 (0.04 - 0.84) 0.24 (0.15 - 0.37) 644.37 8.01 0.24 264.37 228.71       
   AE† 0.76 (0.60 - 0.85)  0.24 (0.14 - 0.40) 647.55 11.20 0.13 265.55 230.11 3.19 1 0.07 
   E   1.00 (1.00 - 1.00) 701.58 65.23 <0.001 317.58 180.68 57.21 2 <0.001 Sinus of ACE ACE 0.83 (0.57 - 0.89) 0.00 (0.00 - 0.26) 0.17 (0.11 - 0.26) 870.39 9.92 0.13 490.39 -2.68       
 Valsalva  AE 0.83 (0.74 - 0.89)  0.17 (0.11 - 0.26) 870.39 9.92 0.19 488.39 -7.28 0.00 1 1.00    CE  0.61 (0.46 - 0.71) 0.39 (0.29 - 0.54) 892.37 31.90 <0.001 510.37 14.70 21.98 1 <0.001    E   1.00 (1.00 - 1.00) 937.36 76.90 <0.001 553.36 55.10 66.97 2 <0.001   ADE* ADE 0.67 (0.00-0.87) 0.16 (0.00 - 0.84) 0.17 (0.12 - 0.26) 870.27 9.80 0.13 490.27 -2.80       
   AE† 0.83 (0.74 - 0.89)  0.17 (0.11 - 0.26) 870.39 9.92 0.19 488.39 -7.28 0.12 1 0.73 
   E   1.00 (1.00 - 1.00) 937.36 76.90 <0.001 553.36 55.10 67.09 2 <0.001    Sinotubular  ACE ACE 0.82 (0.55 - 0.89) 0.00 (0.00 - 0.24) 0.18 (0.11 - 0.28) 855.52 21.43 <0.001 479.52 -6.45       
 junction  AE 0.82 (0.71 - 0.89)  0.18 (0.11 - 0.29) 855.52 21.43 <0.001 477.52 -11.04 0.00 1 1.00    CE  0.54 (0.36 - 0.68) 0.46 (0.32 - 0.65) 877.71 43.62 <0.001 499.71 11.15 22.18 1 <0.001    E   1.00 (1.00 - 1.00) 911.79 77.70 <0.001 531.79 40.64 56.27 2 <0.001   ADE* ADE 0.47 (0.00 - 0.85) 0.36 (0.00 - 0.86) 0.17 (0.11 - 0.26) 854.86 20.77 <0.001 478.86 -7.12       
   AE† 0.82 (0.71 - 0.89)  0.18 (0.11 - 0.29) 855.52 21.43 <0.001 477.52 -11.04 0.67 1 0.41 
   E   1.00 (1.00 - 1.00) 911.79 77.70 <0.001 531.79 40.64 56.93 2 <0.001 Ascending  ACE ACE 0.75 (0.23 - 0.84) 0.00 (0.00 - 0.46) 0.25 (0.15 - 0.41) 926.48 3.17 0.67 550.48 64.51       
 aorta  AE 0.75 (0.60 - 0.85)  0.25 (0.15 - 0.40) 926.48 3.17 0.79 548.48 59.92 0.00 1 1.00    CE  0.55 (0.35 - 0.70) 0.45 (0.29 - 0.65 939.14 15.83 0.01 561.14 72.58 12.66 1 <0.001    E   1.00 (1.00 - 1.00) 974.95 51.64 <0.001 594.95 103.80 48.47 2 <0.001   ADE* ADE 0.57 (0.00 - 0.82) 0.18 (0.00 - 0.81) 0.25 (0.15 - 0.39) 926.34 3.03 0.69 550.34 64.37    
   AE† 0.75 (0.59 - 0.85)  0.25 (0.15 - 0.41) 926.48 3.17 0.79 548.48 59.92 0.14 1 0.71 
   E   1.00 (1.00 - 1.009 974.95 51.64 <0.001 594.95 103.80 48.60 2 <0.001  
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Table 12. Detailed results of structured equation models (ACE and ADE) for aortic root diameters as measured by TTE 
Bootstrapped confidence intervals are represented in parenthesis. * indicate most parsimonious full model based on AIC and BIC values. 
 † indicates most parsimonious submodel based on likelihood difference test. A: additive genetic effects; C: common environmental 
effects; D: dominant genetic effects; E: unique environmental effects; -2LL: minus 2 log-likelihood values; AIC: Akaike information 
criterion; BIC: Bayesian information criterion; df: degrees of freedom 
 
Variable Full model 
Estimated 
parameters A C or D E -2LL 
Difference 
to 
Saturated 
model 
 -2LL 
Likelihood 
ratio test  
p 
AIC BIC 
Difference 
to Full 
model  
-2LL 
Difference 
to Full 
model  
df 
Difference 
to Full 
model  
p 
LVOT ACE* ACE 0.29 (0.00 - 0.52) 0.09 (0.00 - 0.52) 0.62 (0.44 - 0.90) 790.62 7.29 0.30 430.62 -27.18    
   AE† 0.38 (0.09 - 0.56)  0.62 (0.44 - 0.91) 790.67 7.34 0.39 428.67 -31.66 0.06 1 0.81 
   CE  0.33 (0.07 - 0.52) 0.67 (0.48 - 0.92) 791.16 7.83 0.35 429.16 -31.18 0.54 1 0.46    E   1.00 (1.00 - 1.00) 801.79 18.46 0.02 437.79 -25.09 11.18 2 <0.001   ADE ADE 0.38 (0.00 - 0.53) 0.00 (0.00 - 0.50) 0.62 (0.44 - 0.89) 790.67 7.34 0.29 430.67 -27.12       
   AE 0.38 (0.09 - 0.56)  0.62 (0.43 - 0.91) 790.67 7.34 0.39 428.67 -31.66 0.00 1 1.00    E   1.00 (1.00 - 1.00) 801.79 18.46 0.02 437.79 -25.09 11.12 2 <0.001 Annulus ACE* ACE 0.14 (0.00 - 0.64) 0.36 (0.00 - 0.57) 0.50 (0.31 - 0.71) 787.52 3.87 0.69 427.52 -30.27       
   AE 0.53 (0.31 - 0.69)  0.47 (0.31 - 0.69) 789.05 5.40 0.61 427.05 -33.29 1.53 1 0.22 
   CE†  0.47 (0.29 - 0.62) 0.53 (0.38 - 0.74) 787.74 4.09 0.77 425.74 -34.60 0.22 1 0.64 
   E   1.00 (1.00 - 1.00) 810.96 27.32 <0.001 446.96 -15.92 23.44 2 <0.001   ADE ADE 0.53 (0.00 - 0.69) 0.00 (0.00 - 0.50) 0.47 (0.30 - 0.72) 789.05 5.40 0.49 429.05 -28.74       
   AE 0.53 (0.30 - 0.69)  0.47 (0.31 - 0.70) 789.05 5.40 0.61 427.05 -33.29 0.00 1 1.00    E   1.00 (1.00 - 1.00) 810.96 27.32 <0.001 446.96 -15.92 21.91 2 <0.001 Sinus of  ACE* ACE 0.00 (0.00 - 0.67) 0.62 (0.08 - 0.72) 0.38 (0.16 - 0.57) 1058.5 11.04 0.09 702.50 251.70       
 Valsalva  AE 0.64 (0.41 - 0.84)  0.36 (0.16 - 0.59) 1063.8 16.37 0.02 705.83 252.50 5.33 1 0.02 
   CE†  0.63 (0.44 - 0.78) 0.37 (0.22 - 0.56) 1058.5 11.04 0.14 700.50 247.17 0.00 1 1.00 
   E   1.00 (1.00 - 1.00) 1104.6 57.09 <0.001 744.55 288.68 46.05 2 <0.001   ADE ADE 0.64 (0.41 - 0.83) 0.00 (0.00 - 0.00) 0.36 (0.16 - 0.58) 1063.8 16.37 0.01 707.83 257.03       
   AE 0.64 (0.41 - 0.83)  0.36 (0.16 - 0.58) 1063.8 16.37 0.02 705.83 252.50 0.00 1 1.00    E   1.00 (1.00 - 1.00) 1104.6 57.09 <0.001 744.55 288.68 40.72 2 <0.001 Sinotubular  ACE* ACE 0.26 (0.00 - 0.75) 0.25 (0.00 - 0.53) 0.49 (0.22 - 0.70) 808.23 8.28 0.22 492.23 110.06       
junction   AE 0.53 (0.32 - 0.77)  0.47 (0.23 - 0.69) 808.95 8.99 0.25 490.95 106.35 0.72 1 0.40 
   CE†  0.45 (0.26 - 0.59) 0.55 (0.41 - 0.74) 808.88 8.92 0.26 490.88 106.28 0.64 1 0.42 
   E   1.00 (1.00 - 1.00) 827.34 27.39 <0.001 507.34 120.33 19.11 2 <0.001   ADE ADE 0.53 (0.00 - 0.72) 0.00 (0.00 - 0.64) 0.47 (0.21 - 0.69) 808.95 8.99 0.17 492.95 110.77       
   AE 0.53 (0.31 - 0.77)  0.47 (0.22 - 0.69) 808.95 8.99 0.25 490.95 106.35 0.00 1 1.00    E   1.00 )1.00 - 1.00 827.34 27.39 <0.001 507.34 120.33 18.39 2 <0.001 Ascending  ACE* ACE 0.48 (0.00 - 0.79) 0.18 (0.00 - 0.56) 0.34 (0.19 - 0.56) 898.31 4.65 0.59 558.31 135.25       
 aorta  AE† 0.67 (0.45 - 0.82)  0.33 (0.18 - 0.55) 898.75 5.09 0.65 556.75 131.20 0.44 1 0.51 
   CE  0.55 (0.37 - 0.68) 0.45 (0.32 - 0.63) 901.68 8.02 0.33 559.68 134.13 3.37 1 0.07    E   1.00 (1.00 - 1.00) 933.64 39.98 <0.001 589.64 161.60 35.33 2 <0.001   ADE ADE 0.67 (0.00 - 0.80) 0.00 (0.00 - 0.65) 0.33 (0.18 - 0.54) 898.75 5.09 0.53 558.75 135.68       AE 0.67 (0.45 - 0.81)  0.33 (0.19 - 0.54) 898.75 5.09 0.65 556.75 131.20 0.00 1 1.00    E   1.00 (1.00 - 1.00) 933.64 39.98 <0.001 589.64 161.60 34.89 2 <0.001 
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5.  DISCUSSION 
5.1  Systolic image reconstruction by using absolute delay 
We found that coronary artery velocity during late systole is independent of HR and 
between 260-340 ms mean velocities were significantly lower. The relatively fixed 
length of the systole versus diastole is a well-understood phenomenon. At higher HRs, 
the diastasis period shortens, and above HR of 96 bpm it eventually disappears [31, 88, 
89]. Thus, cardiac CT phase reconstructions at end-systole are often considered. Several 
previous studies investigated image acquisitions performed during this period [4, 37, 
90-92]. One study sought to assess the optimal systolic and diastolic phase 
reconstruction during coronary CTA [4].  Motion of the coronary arteries was scored on 
a 1-5 motion scale (1: no motion artifacts; 5: severe motion artifacts), in 5% steps 
throughout the R-R interval. In patients with HR<70 bpm, significantly lower scores 
were found during diastole vs. systole, while in patients with HR>80 bpm, systole 
provided significantly lower motion scores. The least coronary motion during diastole 
was found at 75% reconstruction window and during systole at 30% and 35% 
reconstruction windows. Another study evaluated the robustness of the end-systolic 
temporal windows in patients with HR>65 bpm [90]. In contrast with the previous study 
motion of the coronary arteries was evaluated during a predefined temporal window of 
200-400 ms. Results suggest, that a 100 ms long end-systolic temporal window is able 
to provide acceptable image quality at any heart rate. A prior investigation [31] directly 
compared the image quality and artifacts of the aortic and mitral valves using relative 
and absolute delay reconstructions. Their results indicate that the absolute delay image 
reconstruction provides superior image quality with less motion artifacts. These 
differences are due to HR variability, as in patients with higher HR the diastole shortens 
which leads to the non-proportional decrease of the R-R interval [35]. For example, in a 
patient with HR of 78 bpm (R-R cycle length of 770 ms), a 40 % relative R-R phase 
reconstruction corresponds to 308 ms (i.e. mid systole), whereas at a heat rate of 57 
bpm (R-R cycle length of 1,050 ms), a reconstruction interval, placed at 40 % displaces 
to a 420 ms absolute delay (i.e. end-systole) (Table 13 and Figure 20). Therefore when 
using traditional relative phase percentage reconstructions the specified period of the 
cardiac cycle is highly variable at differing HRs.  
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 Table 13. Reconstruction times at 10 % phase increment for HR = 78 and 57 bpm [75] 
 
Figure 20. Relative vs. absolute reconstruction interval at HR of 78 and 57 bpm [75] 
Velocity maps of two different patients’ RCAs using A: relative delay (% of the R-R 
interval, x-axis), and B: absolute delay (ms of the R-R interval, x-axis) demonstrate 
differences in minimal systolic velocities. Vertical line is placed at 40 % of the R-R 
cycle, which at HR of 78 bpm corresponds to an absolute delay of 308 ms and at HR of 
57 bpm to an absolute delay of 420 ms. Note that despite highly disparate HR, the 
minimal velocity time point lies similarly close to 400 ms after the R-wave. 
 
HR = 57 bpm 
Phases (%) Time (ms) 
Velocity 
(mm/s) 
10 105 22.6 
20 210 79.8 
30 315 32.0 
40 420 7.9 
50 525 32.5 
60 630 38.1 
70 735 26.3 
80 840 14.0 
90 945 22.6 
HR = 78 bpm 
Phases (%) Time (ms) 
Velocity 
(mm/s) 
10 77 60.2 
20 154 28.9 
30 231 36.2 
40 308 32.2 
50 385 14.4 
60 462 41.8 
70 539 18.9 
80 616 28.2 
90 693 45.1 
A 
B 
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In our study the image reconstructions performed using an absolute delay resulted in 
selected phases with good or excellent image quality in all patients, as clinically deemed 
and reported. Thus all selected coronary artery landmarks could be visualized and their 
location precisely analyzed, albeit at slightly differing time points. Accordingly, we 
calculated the optimal velocities of the selected coronary arteries and examined the 
motions’ HR dependency. We found no significant correlation between the HR and 
coronary artery motion velocities, except for the AM1 branch.  
The selected absolute delay interval in our study (200-420 ms) corresponds to the time-
interval of the ventricular systole and extends between the peak of the R-wave and the 
T-wave or the descending T-wave of the electrocardiogram. Physiologically, ventricular 
systole is divided into two periods: the isovolumic contraction phase and the ejection 
phase. The ejection phase consists of an early phase when the maximum ejection occurs 
and a latter phase with reduced or absent ejection [35]. The reduced phase is 
immediately followed by the proto-diastole and the isovolumic relaxation. Physiological 
investigations revealed an inert systolic phase with a constant low motion at the end of 
systole and early diastole, thus providing a basis for late-systolic/early diastolic cardiac 
CT acquisitions [32].  
A previous study sought to assess the durations of the left ventricular systolic phases, 
including the isovolumic contraction time (ICT), the pre-ejection period (PEP) and the 
left ventricular ejection time (LVET) [93]. According to their measurements, the mean 
ICT was 70 ± 9.5 ms with a range of 51-90 ms, the mean PEP was 100 ± 13 ms with a 
range of 78-130 ms and the mean LVET was 281 ± 21 ms, ranging from 230 to 334 ms.  
In our study we found that the optimal time points with lowest coronary motion ranged 
from an average phase start time of 273 ms in the origin of the LM to 329 ms in the AM 
branch (Table 2). These findings are congruent with our findings that the mean 
coronary artery motion velocities were significantly lower in the mid period of the 
selected temporal window, between 280 and 340 ms (Figure 16). Thus we found that 
the lowest coronary motion occurs during the LVET, in its second half during reduced 
ejection through the following proto-diastole, and confirms the previous works 
reporting the existence of an inert constant low motion end-systolic early diastolic 
temporal window.  
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To our knowledge, no other previous studies have investigated the image quality during 
the end-systolic temporal window by using absolute delay image reconstruction based 
on the coronary artery motion in patients with different HRs.  
We believe our findings have three applications in the current era of cardiac CT. First, 
as prior work has established, systolic targets are highly useful in the setting of 
tachycardia and arrhythmia, in order to salvage diagnostic coronary CTA [4]. Second, 
as described in the multimodality imaging guideline for aortic valve intervention, 
evaluation can be improved by systolic absolute-delay reconstructions, of particular 
importance given the now well-established role of cardiac CTA for TAVI planning [94]. 
Third, the field of myocardial stress perfusion CT is emerging, and image acquisitions 
are performed during the administration of pharmacologic vasodilator stress agents; 
these agents raise HRs, often shortening or eliminating diastolic windows for 
acquisition. Because acute beta-blockade has been shown to decrease the efficacy of 
pharmacologic stress, the ability to image in systole may be a key element to the 
performance of stress perfusion CT, which is technically challenging and depends upon 
concomitant coronary artery imaging [95, 96]. 
 
 
  
DOI:10.14753/SE.2017.2024
 56 
5.2 The use of esmolol before coronary CTA 
In this randomized, single-center clinical trial we compared IV esmolol vs. IV 
metoprolol for HR control in patients who underwent coronary CTA because of 
suspected CAD. We showed that esmolol with a stepwise bolus administration protocol 
is at least as efficacious as the standard of care metoprolol to achieve the optimal HR 
(<65 bpm) during coronary CTA. Furthermore, we have demonstrated that IV esmolol 
allows a safe HR control for coronary CTA examination even if it is administered in 
relatively high doses with a dosage scheme independent of body weight. 
Esmolol is an ultrashort-acting IV β-blocker. The rapid onset and offset of effects of 
esmolol make this IV drug a potential alternative of the standard of care metoprolol in 
the daily routine coronary CTA service. Especially, coronary CTA services with no 
access to cardiology or intensive care background might benefit most of this ultrashort-
acting medication. The recommended administration protocol of IV esmolol with 
infusion pump is relatively complex and precluded its widespread use in the diagnostic 
facilities. Different dosage schedules have been developed depending on clinical setting 
and diagnosis. Generally, a loading dose of <500 μg/kg/min over 1 minute is 
administered followed by a continuous infusion of 25–300 μg/kg/min [82].  We showed 
that esmolol is safe and efficacious if administered in boluses without the subsequent 
continuous infusion. The “bolus only” administration protocol of esmolol would make 
this IV β-blocker a real life alternative of IV metoprolol. In this clinical trial we used a 
body weight-independent administration protocol with stepwise increments in dose in 
every 3 minutes. Importantly, the timing of the administration of the IV esmolol boli 
was similar to the metoprolol administration protocol; therefore, it did not slow down 
our routine clinical cardiac CT workflow. Our choice of 100-mg IV esmolol for the 
initial bolus is based on a previous observational study that showed that the dose of 
2 mg/kg (for a 70-kg patient this equals 140-mg esmolol) is safe to administer before 
the coronary CTA examination [97]. If 100-mg dose proved to be ineffective, and the 
patients’ HR did not reach the predefined ≤65 bpm in 3 minutes, we have increased the 
bolus to 200-mg IV esmolol. Finally, if the HR did not change after an additional 3-
minute period (testing during a Valsalva maneuver as well), we administered the third, 
once again 200-mg, bolus of IV esmolol. We have not added further boluses; thus, the 
maximum administered IV esmolol was 500 mg during an approximately 6- to 7-
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minutes time period. Of note, only about one-third of patients have received the full 
dose of esmolol and two-thirds of patients have reached the target HR with ≤300-mg 
esmolol dose. We have stopped the patient enrollment as early as the interim analysis 
indicated that esmolol is clearly non-inferior to metoprolol; in fact, it showed 
superiority characteristics as the responder proportion in the esmolol group was 89% vs. 
the metoprolol group's 78%. 
A previous study [97] demonstrated the safety and efficacy of IV esmolol in 391 
patients. In this prospective study, HR was reduced from 80 ± 11 bpm to 63 ± 7 bpm  
and HR <65 bpm was achieved in 65% of the patients. Four of the 391 patients (1%) 
have experienced a final HR of <50 bpm; however, all 4 remained asymptomatic and 
the bradycardia resolved in minutes without any intervention with atropine or temporary 
pacing. Moreover, this study reported a 0.5% incidence of transient hypotension 
(systolic BP <100 mm Hg). In our clinical trial, we have reached a higher responder 
proportion (89.2%) probably because of a more aggressive dosing scheme. Importantly, 
none of the 204 patients who received esmolol had severe bradycardia (minimum HR 
was 53 bpm). On the other hand, transient hypotension (systolic BP <100 mm Hg) was 
observed in 9.3% of the patients immediately after the scan in the esmolol group, which 
was significantly higher compared to the metoprolol groups’ 3.8%. Importantly, 
30 minutes after the scan this decreased to 2.5% in the esmolol group, whereas in the 
metoprolol group the percentage of patients with hypotension did not change (3.8%). 
None of the patients had clinically significant adverse event. Thus, the stepwise bolus 
administration of esmolol is safe and it is well tolerated among patients with normal left 
ventricular function scheduled to undergo coronary CTA examination. Furthermore, our 
data show that IV esmolol is at least as efficacious as IV metoprolol to reach optimal 
HR during coronary CTA. 
Many centers are reluctant to administer IV medication for HR control during coronary 
CTA owing to the fear from potential side effects. Another study [98] reported minor 
complications (transient hypotension) related to IV metoprolol administration only in 
1.47% and major complications (not resolving with observation of analgesia) in 0.44% 
of patients who underwent coronary CTA. These results demonstrate that IV metoprolol 
is a safe drug to use for this purpose in patients with normal left ventricular function 
although the study was underpowered to assess for rare major complications. 
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Esmolol is metabolized via rapid hydrolysis by red blood cell esterases, independent of 
the hepatic and renal function [99]. It is routinely administered during perioperative 
intensive care and before laryngoscopy and tracheal intubation procedures to prevent 
hypertension and tachycardia [100, 101]. In this clinical trial, we have excluded patients 
with contraindications to β-blockers such as asthma. However, it has been demonstrated 
previously that esmolol is safe in bronchospastic diseases [102]. 
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5.3 Impact of the imaging method on heritability of the aortic root 
The purpose of our study was to investigate the influence of the imaging method on the 
heritability estimates of the aortic root dimensions. The main finding of our study is that 
the CTA-derived measurements suggest a stronger heritability of the aortic root 
configuration. TTE-derived measurements showed moderate to no genetic influence.  
CTA- and TTE-measured diameters were similar between MZ and DZ twins, however 
TTE significantly underestimated the diameters of LVOT, annulus and sinotubular 
junction as compared to CTA (Table 8).  
Intra-reader reproducibility of TTE was excellent similarly to CTA, however inter-
reader reproducibility of TTE was substantially lower than CTA in case of all 
parameters (Table 9).  
In line with our expectations we observed stronger correlations in the MZ twins 
compared to DZ twins, independent of the imaging technique (Table 10). However, 
differences between MZ and DZ correlations were substantially higher when using 
CTA-derived measurements. These differences in correlation values might be the 
consequence of the inherent properties (e.g. reproducibility, accuracy) of the two 
imaging modalities. While TTE provides reliable functional information, CTA gives 
more precise anatomical evaluation. Previous studies have demonstrated that TTE-
derived annulus diameters are substantially smaller compared to CTA-based 
measurements [69, 103]. Due to the complex shape of the annulus its diameter might 
vary according to the location where it was measured. Therefore underestimation might 
be attributable to the 2D nature of TTE, which limits precise measurement.  
Measurement inconsistencies between the two imaging methods can result in 
differences in heritability components. A substudy of the Strong Heart Study sought to 
assess the heredity of aortic root diameter in family members using TTE. The 
heritability of the aortic root was 0.44, which indicates that a major proportion of 
phenotypic variance is due to environmental factors [63]. Another study that 
investigated the heritability of the aortic root diameter showed 0.49 heritability 
estimates [67].  
Our TTE-based heritability estimates also confirm these findings, showing lower 
genetic determination of the aortic root compared to CTA. Specifically, LVOT and 
ascending aorta resulted in AE models, while the annulus, sinus of Valsalva and 
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sinotubular junction resulted in CE models, indicating the superiority of environmental 
factors over additive genetic factors (Figure 19, Table 12). Technical limitations of 
TTE such as suboptimal echo window, chest and body configuration of the patient 
contribute to the accumulation of potential measurement errors, which might appear as 
part of the unique environmental effects. 
In case of CTA AE models showed that aortic root diameters are mostly determined by 
the additive effect of genes (Figure 19, Table 11). The superior reproducibility and 
precise measurement capability of CTA resulted in higher heritability estimates of aortic 
components. These results suggest that the extent of heritability estimates strongly 
depends on the imaging method.  
It is recognised that genetics play an important role in the development of aortic 
pathology. In general, two approaches exist for the identification of genes susceptible 
for the trait or disorder. Candidate gene studies aim to assess the association between 
pre-specified genes of interest and phenotypic variance or disorder. In contrast, genome-
wide association studies (GWAS) scan the entire genome and provide information of 
genetic variations. Previous studies demonstrated that thoracic aortic aneurysms are 
associated with multiple genetic mutations. TGFBR1 (transforming growth factor-beta 
receptor type 1) and TGFRB2 mutations are frequently identified in aortic aneurysms 
[104, 105] and are responsible for pathological aortic tissue degeneration, so called 
cystic medial necrosis [106]. A combined GWAS and candidate gene study investigated 
11 families with aortic aneurysms and discovered a novel mutation in gene TGFBR3, 
which is also significantly associated with thoracic and abdominal aneurysm as well as 
mitral valve disease [107]. Aortic aneurysms showed strong familial accumulation, 
therefore authors recommended a close-follow up of family members and yearly 
echocardiographic imaging of the aortic root with at least one baseline imaging of the 
whole aorta including side branches in patients carrying this mutation.  
CTA plays a key role for diagnosing patients at potential risk for aortic aneurysms. 
Despite the drawback of the radiation exposure and the administration of IV contrast 
agent, CTA provides precise measurement of the complex configuration of the aorta and 
side branches. Moreover, it is able to assess calcifications and thrombi, thus providing 
better risk stratification of patients undergoing surgical procedures.  
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5.4  Limitations 
There are some limitations regarding the listed studies that have to be considered.  
The optimal systolic phase investigations has a small cohort of 21 patients, however it is 
sufficient number to give 1488 landmark points for velocity evaluation. This study was 
also a single center and a single vendor study. We used a second-generation dual source 
scanner, which gave temporal resolution of 75 ms, which is relatively low as compared 
to commonly available single-source scanners; since our data was acquired, native 
temporal resolutions have been decreased to 66 ms with more modern scanners. Motion 
could also be confounded by respiratory motion artifact, which is very difficult to 
subtract from the final image. Lastly, our vendor’s definition of a phase was the “phase 
start”; whereas other vendors may define a phase reconstruction by the “phase center” 
and this careful distinction is important if generalizing our findings to other systems. 
The esmolol vs. metoprolol study was a single-center study; therefore, the efficacy and 
safety of the described esmolol bolus protocol has to be evaluated in a multicenter 
randomized controlled trial. As the administration protocols and the injected volumes 
were different for the IV metoprolol and IV esmolol groups, it was not feasible to blind 
the physicians to the drug they were administering. The combined use of oral and IV β-
blocker protocols for HR control might limit the generalizability of our results for IV-
only protocols. Owing to the oral metoprolol pretreatment, our findings do not 
demonstrate that esmolol IV alone vs. metoprolol IV is as or more effective for HR 
control. However, it is important to note that the combined use of oral and IV β-
blockers is a widely used and effective strategy for HR lowering before coronary CTA 
[6, 108]. In this scenario, esmolol is at least as efficacious as IV metoprolol. The 
response rate to oral metoprolol was relatively low in our study (162 of 574 [28%]), 
which might have been higher with the use of a more aggressive administration regime 
(e.g. 100-mg oral metoprolol if HR >65 bpm) [82]. Furthermore, we did not test smaller 
doses of esmolol (e.g. 50–100 mg), which might be equally efficacious.  
Regarding the heritability estimates of the aortic root the sample size of our population 
was moderate compared to population-based twin registries, nonetheless the 
multimodality nature of our study provides more robust measurements than earlier 
investigations. Second, CTA and TTE measurements were not performed exactly in the 
same time of the cardiac cycle (mid-diastole vs. mid-systole to end-diastole, 
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respectively). However, in a previous study no significant differences were found in the 
size of the annulus during the cardiac cycle [60]. Finally, due to the length of the TTE 
protocol, only one regular and one zoomed parasternal long-axis loop was acquired 
consisting of 3 cardiac cycles each. Optimal measurements were selected on an offline 
basis, which resulted in fair intra- and inter-reader reproducibility.  
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5.5  Future perspectives 
Impaired image quality is frequently attributable to motion artifacts, which lead to 
higher incidence of non-diagnostic coronary segments. Image acquisition during systole 
is of great importance in patients with higher and/or variable HR, when the length of 
diastole shortens.  
In the past years, CTA has emerged as a non-invasive imaging technique for left atrial 
and pulmonary vein image acquisition in patients referred for radio-frequency catheter 
ablation (RFCA) [109]. The 3D nature of CTA allows for precise visualization of the 
complex shape of the left atrium and pulmonary veins, besides it enables to obtain 
CAD, which was previously shown to have higher prevalence in patients with atrial 
fibrillation [110, 111]. However, patients undergoing CTA before RFCA frequently 
show up with cardiac arrhythmia, which hampers the evaluation of the coronary 
arteries. By refining the systolic temporal window diagnostic image quality can be 
reached also in this patient population, which eventually aids the diagnosis of CAD.  
Moreover, in the era of TAVI procedures systolic image acquisition is increasingly 
important. Acquisition of the aortic root and the heart by CTA prior to TAVI is 
performed during systole, due to the fact that aortic annulus area and mean diameter are 
larger during systole [112, 113]. When performing TAVI calcifications are 
displaced/crushed by the prosthesis with a risk of potential coronary occlusion. A 
predefined systolic temporal window where the coronary arteries move the least might 
be very helpful to achieve precise measurement, thus avoiding future complications. 
Moreover, CTA is able to provide valuable information regarding the amount and 
distribution of calcification in the aortic root and peripheral vasculature. Reproducibility 
is also essential when measuring geometry of anatomical complex structures. A 
previous study showed that the use of automated post-processing imaging software for 
annular measurement before TAVI was better in predicting the occurrence of post-
procedural aortic regurgitation compared with the manual measurements [114]. In our 
heritability study we also demonstrated that the use of semi-automated algorithm 
provides reliable intra and inter-reader measurements of the complex aortic root. In the 
future more feasibility studies regarding the use of semi/fully automated software 
algorithms prior to TAVI as a part of the clinical routine are expected.  
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Furthermore, recently several investigations focused on the detection of coronary 
microvascular dysfunction. The spatial resolution of current CT scanners (≈ 400 μm) 
limits the precise detection of microvascular disease, however future technical advances 
in stress induced CT myocardial perfusion might serve as a non-invasive imaging 
method for detecting microsvascular disease [115]. Adenosine stress-rest cardiac CT is 
able to identify myocardial perfusion defects and as such is capable of reducing the 
number of false positive CTA findings [116, 117]. However, the use of adenosine 
entails the increase of HR, thus reducing the image quality. The end-systolic period 
might allow for better image quality therefore in the future the number of investigations 
regarding systolic image acquisitions is expected to increase.  
Administration of HR lowering medications prior to CTA aids to improve image 
quality. To date metoprolol is the most frequently used β-blocker in patients with 
HR>65 bpm. However, there are several conditions when the use of metoprolol is 
contraindicated. Our study demonstrated that the use of esmolol prior to CTA 
examination is simple, effective and safe. Therefore if contraindications are present 
esmolol is an alternative method to achieve the desirable HR and image quality. It is 
important to note that esmolol is more expensive than IV metoprolol. However, the 
effective and short duration of HR control achievable with esmolol might result in wider 
usage of this IV β-blocker in cardiac CT labors, which would increase the percentage of 
patients scanned with optimal HR and improve the diagnostic performance of CTA. A 
larger multicenter trial is warranted to adequately explore the cost-effectiveness of 
esmolol use in the coronary CTA laboratories.  
Imaging with CTA revealed a greater genetic influence compared to TTE as it provides 
more reliable measurements of the complex aortic root. Therefore, the choice of 
imaging technique is crucial in heritability studies. Moreover, our study demonstrated 
that image acquisition by CTA is indispensable when performing structural heart 
disease interventions. Recently, the usefulness of CTA was shown in sizing of 
transcatheter caval valve implantation (CAVI) [118]. Based on 3D CTA images 3D 
printing of right atrium-inferior vena cava (RA-IVC) topography was performed that 
aided the transcatheter valve selection (Figure 21). Therefore in the future CTA is 
expected to play a key role in 3D printing and planning of complex procedures.   
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Figure 21. CTA guided 3D printing for selection of the appropriate size of SAPIEN XT 
Valve for caval valve implantation [118] 
A: visualization of right atrium-inferior vena cava (RA-IVC) junction plane; B: the first 
hepatic vein; C: height measured between the two structures aids optimal valve 
positioning without the obstruction of the hepatic vein; D: sequential measurements in 
horizontal planes 1 cm below the RA-IVC junction and 1 cm above the first identified 
hepatic vein for valve sizing; E: 3D printed models of the RA-IVC junction with 
SAPIEN 26XT and 29XT (Edwards Lifesciences Corp., Irvine, California) valve 
mockups inserted for fit testing; When using SAPIEN 26XT valve a gap occurred 
between the IVC lining and the valve frame, which raised concerns about the 
development of perivalvular leak, hence the SAPIEN 29XT valve was chosen.  
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6. CONCLUSIONS 
CTA is a technically demanding procedure, and motion artifacts present the chief 
challenge unique to ECG-gated coronary CTA. Diagnostic image quality can be 
achieved by synchronizing the acquisition window to the phase of the cardiac cycle with 
minimal coronary arterial motion. Coronary CTA image acquisitions are typically 
performed in the most quiescent period of the cardiac cycle, which at low and stable HR 
is during mid-diastole. However, in patients with higher HR, the end-systolic and early-
diastolic reconstructions are more favorable. In our study we found that during an 
absolute delay of 200-420 ms after the R-wave, the ideal reconstruction interval varies 
significantly among coronary artery segments. Decreased coronary artery velocities 
occur between 280 to 340 ms of the cardiac cycle. Therefore a narrow range of systolic 
intervals, rather than a single phase should be acquired.  
 
Coronary CTA is an established tool to rule out CAD. Diagnostic accuracy of coronary 
CTA is highly dependent on patients' HR. Despite widespread use of β-blockers before 
coronary CTA, only few studies have compared various agents used to achieve adequate 
HR control. In our study we sought to assess whether the ultrashort-acting β-blocker IV 
esmolol is at least as efficacious as the standard of care IV metoprolol for HR control 
during coronary CTA. Our results suggest that IV esmolol with a stepwise bolus 
administration protocol is at least as efficacious as the standard of care IV metoprolol 
for HR control in patients who undergo coronary CTA.  
 
Heritability plays an important role in the configuration of the aortic root. Previous 
heritability studies of the aortic root used TTE for the assessment of aortic root 
dimensions and showed weak to moderate heritability. CTA might enable more accurate 
measurements and better estimation of heritability. In our study we showed that CTA-
derived metrics resulted in stronger heritability of the aortic root, as compared to TTE-
derived measurements, which showed moderate to no genetic influence. These results 
suggest that the imaging method has a considerable impact on the heritability estimates 
and metrics of the aortic root.  
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7.  SUMMARY  
In the past decade Computed Tomography Angiography (CTA) has emerged an 
essential diagnostic imaging modality for the evaluation of the coronary artery tree and 
the aortic root. Improved temporal and spatial resolution of current CT scanners allow 
for accurate detection of coronary atherosclerosis, while the 3-dimensional nature of 
CTA provides accurate and reproducible measurements of complex anatomical 
structures. However, precise evaluation of the images requires the optimization of 
image quality. Adequate timing of image acquisition and suitable use of premedication 
enable to achieve diagnostic image quality.  
We defined the optimal systolic reconstruction interval by using absolute delays. We 
found that coronary artery velocity during late systole is independent of heart rate (HR) 
and in the mid period of the selected systolic time-interval mean coronary artery 
velocities were significantly lower.  
We also demonstrated that ultra-short time intravenous (IV) esmolol prior to CTA is at 
least as efficacious, as metoprolol to achieve the optimal HR (<65 bpm). Furthermore, 
we have shown that IV esmolol allows for safe HR control even if it is administered in 
relatively high doses. 
We showed that inherent properties of CTA and the use of semi-automated post-
processing software allow for more accurate and reproducible measurement of aortic 
root dimensions compared with transthoracic echocardiography (TTE). Inaccurate 
measurements artificially inflate the magnitude of the environmental component in the 
heritability estimates of aortic root. In our twin study TTE-based measurements showed 
moderate to no genetic influence, while CTA-based measurements suggested that aortic 
root dimensions are predominantly determined by genetic factors. Therefore, the choice 
of imaging method has a substantial impact on heritability estimates.  
Our results emphasize that optimal image quality during cardiac CTA allows for the 
diagnosis of coronary artery disease as well as precise and reproducible measurements 
of complex anatomical structures, which are utmost importance in the era of structural 
heart disease interventions.  
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8. ÖSSZEFOGLALÁS 
Az elmúlt évtizedben a komputer tomográfia angiográfianak (CTA) egyre nagyobb 
szerepe van a koszorúerek és az aortagyök vizsgálatában. A CTA térbeli és időbeli 
felbontóképessége lehetővé teszi a koszorúér-betegség ábrázolását, 3 dimenziós 
sajátossága pontos és reprodukálható méréseket biztosít a bonyolult anatómiájú 
struktúrák esetében. A felvételek pontos értékelése jelentős mértékben függ a 
képminőségtől. A képrekonstrukció pontos időzítése, valamint a betegek megfelelő 
premedikációja lehetővé teszi a diagnosztikus képminőség elérését.  
Munkám során megállapítottam a systoléban végzett képrekonstrukció optimális fázisát. 
Eredményeink alapján a koszorúerek mozgási sebessége a systole késői szakasza alatt a 
szívfrekvenciától független, valamint a vizsgált időintervallum középső szakaszában 
szignifikánsan alacsonyabb, ezért a CTA vizsgálat során a systoléban végzett 
képrekonstrukció a systole ezen szakaszában javasolt.  
Munkám további részében bizonyítottam, hogy a CTA vizsgálat előtti cél-
szívfrekvencia (<65/perc) elérésében az ultra-rövid hatású intravénás esomolol legalább 
annyira hatásos mint a metoprolol, valamint az esmolol akár magasabb dózisának 
alkalmazása is biztonságos szívfrekvenciát eredményez. 
Továbbá megállapítottam, hogy a CTA sajátosságai valamint a fél-automata algoritmus 
használata az aortagyök átmérőinek pontosabb és reprodukálhatóbb méréseit teszi 
lehetővé a transztorakális echocardiográfiához (TTE) képest. A mérési pontatlanság az 
öröklődési vizsgálatok során “arteficiálisan” növelheti a környezeti hatások mértékét. 
Az általunk végzett ikervizsgálatban a TTE-vel mért átmérők mérsékelt öröklődést vagy 
annak teljes hiányát mutatták, míg a CTA-val végzett mérések alapján az aortagyök 
átmérőit leginkább a genetikai tényezők határozták meg. Ezek alapján arra 
következtetünk, hogy a kapott öröklődési értékek jelentős mértékben függnek a 
választott képalkotó módszertől.  
A CTA vizsgálat során az optimális képminőség lehetővé teszi a koszorúér-betegség 
diagnosztizálását, valamint pontos és reprodukálható méréseket biztosít, mely a 
strukturális szívbetegségek intervenciójának elengedhetetlen feltétele. 
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